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Abstract 
Arsenic Trioxide (AS2O3) has been explored for its use as medicine in both 
Western and Chinese societies. It is a major ingredient of arsenic compounds in 
Traditional Chinese Medicine (TCM) and is derived from Pishi by sublimation. In 
1990s, AS2O3 was reported to treat patients with acute promyelocytic leukemia (APL). 
Since then, much of study of arsenic therapy has been focused on APL and other 
leukemia. Only until recently, research on other solid tumor cells was emerged. 
In the present study, the mechanism of AS2O3 treatment of breast cancer, a 
common cancer in women in Hong Kong and worldwide, was investigated. Two 
human breast tumor cell lines were used, estrogen receptor alpha (ERa) positive 
MCF-7 cells line which mimicks early stage of the tumor and E R a negative 
MDA-MB-231 cells line which mimicks late stage of the tumor. This study finds that 
AS2O3 inhibits cell proliferation of MDA-MB-231 cells in a time and dose dependent 
manner and the IC50 of AS2O3 of MDA-MB-231 cells were over 20|iM, 18.4|iM, 
\2.\[iM upon 24, 48, 72 hours treatment respectively. The mechanistic study 
indicated that AS2O3 inhibited cell proliferation via cycle arrest and apoptosis. It 
induced apoptosis via both extrinsic and intrinsic apoptotic pathway by regulating the 
pro- or anti-apoptotic molecules. Moreover, AS2O3 induced cell cycle was arrested at 
G2 phase in MDA-MB-231 cells. 
ii 
In in vivo study, nude mice bearing MCF-7 cells were also used as animal model 
to study the potential of AS2O3 in breast cancer treatment and the probable side effect. 
In this study, AS2O3 was proved to be effective to inhibit the tumor growth without 
severe side effects such as liver or heart tissue damage. 
The study revealed that AS2O3 was more potent than tamoxifen in combating 
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1.1 Breast Cancer 
1.1.1 Introduction to Breast Cancer 
Breast cancer, or breast carcinoma, is a cancer in the breast tissue where the 
proliferation of the cells is out of control and damages the normal breast tissue. It occurs 
not only in women but also in men. 
Breast cancer is the fifth most common cause of cancer death in the world. Among 
women, breast cancer is the most common cancer and the most common cause of cancer 
death in the world (World Health Organization, 2007). 
An estimated 178,480 new cases of invasive breast cancer are estimated to occur 
among women in the United States in 2007. An estimated 40,460 women will die from 
breast cancer. It is forecasted that 2,030 men will be diagnosed and 450 men will die of 
breast cancer in 2007 in the U.S. (American Cancer Society Cancer Facts & Figures, 
2007). Women in the U.S. have 1 in 8 lifetime chance of getting invasive breast cancer 
and a 1 in 33 chance of breast cancer death (American Cancer Association, 2007). Breast 
cancer kills more women in the United States than any other cancers except lung cancer. 
In Hong Kong, breast cancer is the top cancer among women since 1994. In the year 
2001 there were nearly 2000 new cases of breast cancer (Fig. 1.1). One in every 23 Hong 
Kong women will have breast cancer in their life time. Compared to the Western 
countries where 1 in every 10 women will have breast cancer, Hong Kong is lower in 
incidence. However, Hong Kong is above world average in the incidence of breast cancer 
(Foo, 2007). 
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Fig. 1.1 New case numbers of breast cancer by year in Hong Kong 
1.1.2 Types of Breast Cancer 
Breast tumors can be either malignant (cancerous) or benign (non-cancerous). Nine 
out of ten breast lumps are not cancerous and may be fibroadenomas and cysts. The 
difference between malignant and benign tumors is that malignant tumors have the ability 
to invade surrounding areas. Sometimes cells from malignant tumors break away and 
travel to other areas of the body where they may grow and form 'secondary' breast cancer 
tumors. Another name for a secondary tumor is a metastasis. The breasts have a rich 
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blood supply and an extensive lymph gland drainage system, which contribute factors in 
the spread of the disease. 
Breast cancers are grouped as invasive and non-invasive, depending on their ability 
to spread to neighboring tissues: The most common type of non-invasive breast cancer is 
ductal carcinoma in situ (DCIS). Cancer cells are found inside the ducts but have not yet 
spread through the walls of the ducts into the breast tissue. Most people diagnosed with 
DCIS at early stage are able to have the cancer completely removed. In some cases, 
DCIS may develop into an invasive form of breast cancer, if not treated at properly. 
The most common type of invasive breast cancer is called invasive ductal carcinoma 
(IDC) which is responsible for around 80% of all breast cancers. Cancer cells are found 
both in the ducts and in the breast tissue. These cells are also able to metastasize to other 
parts of the body. 
Invasive lobular carcinoma (ILC) accounts for between 10-15% of all breast cancers. 
With ILC, cancer cells grow initially in the lobes of the breast and have the ability to 
spread both to other areas of the breast and to other parts of the body. 
1.1.3 Epidemiologic Risk Factors and Etiology 
The scientists still do not know exactly why women get breast cancer; however, 
there are many risk factors that are thought to be related to breast cancer development. 
The risk factors that people can not control: 
4 
广. 
• Age - the chance of getting breast cancer rises as a woman gets older (Fig 
1.2 and 1.3) 
Age: a major factor 
A woman's chance of getting 
breast cancer iiicreases with 
age. Your chance by your 
citrrcric age is: 
age 20 1 in 1,985 
age 30 1 in 229 
age 40 1 in 68 
age 50 1 in 37 
age 60 1 in 26 
age 70 1 in 24 
ever 1 in 8 
Source： American Cancer Society 
Surveillance Research, 2005. 
Fig 1.2 The chances of getting breast cancer by age. 
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Fig 1.3 The incidence and mortality rates of woman with different age getting 
breast cancer in Hong Kong 
• Genes - there are two genes, BRCAl and BRCA2 that greatly increase the 
risk. Women who have family members with breast or ovarian cancer may wish 
to be tested. 
• Personal factors - started menstruating at an early age (before age 12) or 
went through menopause at a late age (after age 55). 
The other risk factors include overweight, using hormone replacement 
therapy, taking birth control pills, drinking alcohol, not having children or having 
your first child after age 35 or having dense breasts (National Cancer Institute, 
NIH, USA). 
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1.2 Estrogen and Breast Cancer 
Estrogen is a group of steroid hormone which is produced primarily in the ovaries. 
The three major naturally occurring estrogens in women are estradiol, estriol and estrone 
(Fig 1.4). Breast also produced estrogen in a smaller amount. The secondary source of 
estrogen is especially important in estrogen production to help control a woman's 
menstrual cycle (Purohit et al., 1992). 
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estradiol estriol estrone 
Fig 1.4 Structures of three estrogens 
A fundamental theme of more recent studies is that estrogen can modulate a larger 
repertoire of genes through other mechanisms. These include protein - protein 
interactions with other D N A binding transcription factors and through the action of 
membrane associated ER that alters the function of cytoplasmic signal transduction 
proteins (non-genomic actions of estrogen) (Inoue et al., 2004, Santen et al., 2003). 
Estrogens have been found to be the primary stimulant of the breast cancer (Lippman 
et al” 1976, Umans et al., 1984, Hajek et al., 1997). Reverse effects were shown upon 
removal of the ovaries and administration of anti-estrogenic drugs or estrogen synthesis 
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inhibitors (Nadi et al, 1995). And clinical trials showed that about one-third of women 
with metatasitic breast cancer responed positively to estrogen ablation and hormone 
therapy (Kyprianou et al., 1991, Fabian et al., 1994). 
In vitro, the mechanism study demonstrated that estrogen promoted the cell 
proliferation and prevented the apoptosis of breast cancer cells. Estrogen require the 
function of the Ras, mitogen-activated protein kinase (MEK)l and extracellular signal-
regulated kinase (ERK) pathway to induce Gi/S phase transition (Ahamed et al., 2001), 
at elicits down-regulation of the Cdk2 inhibitor pl?*"^ ^ (Foster, 2003, Zhu et al., 2003) to 
increase the cell proliferation by recruite non-cycling cells into cell cycle and to shorten 
the overall cell cycle time. In the ER-positive MCF-7 breast cancer cell line, anti-
apoptotic effects of estrogen have been reported previously (Huang, 1997, Perillo et al, 
2000, Ahamed et al., 2001). Studies indicate that estrogen induces transcription of the 
BCL-2 gene and increases expression of BCL-2 protein, which exerts anti-apoptotic 
action in many cell types (Huang, 1997, Dong et al, 1999, Leung and Wang, 1999). In 
addition to genomic actions, estrogen has been known to exert rapid, likely nongenomic 
actions both in the whole animal and in cultured cells (Szego, 1974, Huang, 1997, 
Razandi et al., 2000). Similar study has also shown the inhibition of U V radiation, TNF-a, 
H2O2, or serum withdrawal induced apoptosis by estrogens through the inhibition of JNK 
activity and B A D activity (Fernando and Wimalasena, 2004). 
However, the majority of breast cancers are estrogen independent, that is their 
development lacks appreciable expression of either the estrogen or progesterone receptors. 
They are estrogen independent. Recent studies demonstrated that increasing the levels of 
circulating estrogens is sufficient to promote the formation and progression of estrogen 
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receptor negative (ER-negative) cancers while, pharmacologically inhibiting estrogen 
synthesis following pregnancy prevents ER-negative tumor formation. It indicated that 
estrogen promoted the growth of ER-negative cancers by acting on cells distinct from the 
cancer cells to stimulate angiogenesis (Gupta and Kuperwasser, 2006). 
1.3 Estrogen Receptor 
An estrogen receptor (ER) is a nuclear receptor for estrogens such as estradiol. It 
occurs both on cell membrane and nucleus. Both receptors have functions independent of 
D N A binding (Levin, 2005). The action of estrogen is mediated through ER. 
Recent studies have revealed the existence of two distinct estrogen receptors in our 
bodies: estrogen receptor alpha (ERa) and estrogen receptor beta (ERP). While they both 
bind estrogen as well as other agonists and antagonists, the two receptors have distinctly 
different localizations and concentrations within our body. Structural differences also 
exist between the two (Fig 1.5). 
AFl 二 ； AF2 (Ugand binding) 
Homology: 2 8% 97% 30% 59% 18% 
E R a ^ ^ Q T r C> 
N-l ^ ; ^ i ； ^ ； \C 
1 180 263 302 SS2 595 
ERii fe ^ r-i. 
I , i 
1 U4 227 255 133^ 530 
(http://en.wikipedia.org/wiki/Estrogen_receptor) 
Fig 1.5 The domain structures of estrogen receptor 
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About 75% of breast cancers are estrogen-receptor-positive ("ER-positive" or 
”ER+"). ERa is certainly associated with more differentiated tumours, while involvement 
of ERp remains controversial. 
1.4 Current Treatment of Breast Cancer 
Today, there's an overwhelming menu of treatment choices for various cancers The 
most common steps are as following: surgery first, followed by chemotherapy and/or 
radiation, and the hormonal (anti-estrogen) therapy is usually started after other 
treatments have been given. 
1.4.1 Chemotherapy 
Chemotherapy is the use of drugs to treat cancer. Chemotherapy works best on 
rapidly dividing cells. Chemotherapy works by stopping the growth or multiplication of 
cancer cells. Some chemotherapy drugs regulate the estrogen receptors. Estrogens 
stimulate the growth by regulation of target genes expression with the recruitment of 
coregulators. Targeting at these coregulatiors can alter the estrogens regulated gene 
expression and in turn the growth of breast cancer (Bevan and Park, 1999). 
In recent years, induction of apoptosis becomes another important mechanism in the 
cancer chemotherapy. The studies show that cytotoxic chemotherapy induced increase in 
apoptosis during treatment (Dive et al., 1992). Further molecular studies demonstrated 
that this "dormant" population was important to characterize the mechanism of their 
resistance to drug therapy (Dowsett et al., 1999). 
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1.4.2 Hormonal (Anti-Estrogenic) Therapy 
As the estrogens and estrogen receptors involve in breast cancer development, 
hormonal therapy can be a very important part of breast cancer treatment. It is especially 
against breast cancer that is hormone-receptor-positive. There are four major kinds of 
hormonal therapy. Depending on personal situation of the patients, doctor will decide 
which one is most appreciate for you. Some of the treatments lower the amount of 
estrogen in the body (Aromatase inhibitors), some block estrogen's ability to lock onto 
the estrogen receptor (selective estrogen-receptor modulators), some destroy the estrogen 
receptor (estrogen-receptor downregulators) and some remove or shut down the major 
source of estrogen production (ovarian shutdown or removal) (breastcancer.org). 
1.4.2.1 Tamoxifen and Other Anti-estrogens 
The anti-estrogen drug that has been used most often is tamoxifen. Tamoxifen is also 
used to treat metastatic breast cancer and to prevent the development of breast cancer in a 
woman at high risk. Tamoxifen worked as an anti-estrogen. It was able to 
treat human breast and on rat mammary tumor and prevent the induction and growth of 
ER positive carcinogen-induced rat mammary carcinomas (Jordan et al., 1976). 
11 
〜< 。〜< 
/ Activation 4'hydr(wytamoxifen 
TAMOXIFEN Prototype ^ 
彻赚 Pure Antiestrogen 
SsJ^ctm ^^ ^ ^^ Receptor Modulators ( > ^^syX^^^ 
\aJ W。 Rii請_a 182.780) 
Raloxiferse Arzoxifene 
q o -
Acoibifene 8a«ecto)of€fTe Lasotoxjfe^e 
Fig 1.6 The tamoxifen and other related nonsteroidal anti-estrogen (Jordana and 
Brodieb, 2007). 
The translational research with tamoxifen to target the ER with the appropriate 
duration (5 years) of adjuvant therapy has contributed to the falling national death rates 
from breast cancer in the U.S. (National Cancer Institute, NCI). Additionally, exploration 
of the endocrine pharmacology of tamoxifen and related non-steroidal anti-estrogen (e.g. 
keoxifene now known as raloxifene) resulted in the recognition of selective ER 
modulation and the translation of the concept to use raloxifene for the prevention of 
osteoporosis and breast cancer (Jordana and Brodieb, 2007) (Fig 1.6). 
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1.4.2.2 Disadvantages of Tamoxifen 
Firstly, tamoxifen is the hormonal treatment as choice for pre-menopausal women 
and shows ineffective in estrogen-receptor (ER) negative patients (i.e. advanced breast 
cancer patients). It has been reported that tamoxifen had little or no effect on estrogen-
receptor-negative tumor cells in culture or on tumors in animals (Lippman et al., 1977， 
Osborne et al., 1985). Furthermore, responses are uncommon (5 to 10 percent) in women 
with estrogen-receptor-negative metastatic breast cancer treated with the drug (Osborne 
et al., 1980). A 1992 meta-analysis of trials of adjuvant therapy suggested that tamoxifen 
had a small but statistically significant survival benefit in these women (Early Breast 
Cancer Trialists Collaborative Group, 1992), but the updated meta-analysis with longer 
follow-up and additional women did not support the conclusion (Early Breast Cancer 
Trialists Collaborative Group, 1998). 
Secondly, beside common side effects caused by all treatments of breast cancer, 
tamoxifen may cause some severe side effects, including blood clots (thrombosis), 
endometrial cancer (cancer of the uterine lining), abnormal growth of uterine tissue 
(endometriosis), stroke, and fertility issues (Osborne, 1998, demons et al., 2002). 
Finally, patients may develop drug resistance within 2-5 years treatment. Over time, 
tamoxifen may lose its anti-estrogen powers. It may end up having no effect that can be 
measured or seen on the breast cells, or even start working like a real estrogen, and begin 
stimulating cancer cell growth instead of decreasing it (Osborne, 1998, Riggins et al., 
2007). Two forms of anti-estrogen resistance occur: de novo resistance and acquired 
resistance. Absence of estrogen receptor (ER) expression is the most common de novo 
resistance mechanism, whereas a complete loss of ER expression is not common in 
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acquired resistance. Anti-estrogen unresponsiveness appears to be the major acquired 
resistance phenotype, with a switch to an anti-estrogen-stimulated growth being a minor 
phenotype. A loss of anti-estrogen responsiveness by initially responsive tumors is likely 
to be the most common acquired resistance phenotype. A different resistance phenotype 
has been described in human breast cancer xenografts that exhibit a switch to a tamoxifen 
(TAM)-stimulated phenotype (demons et cd., 2002, Clarke et al., 2003). 
1.5 Arsenic Trioxide (AS2O3) 
1.5.1 The Characteristics of Arsenic Trioxide (AS2O3) 
Arsenic trioxide (AS2O3) is the most important commercial compound of arsenic, 
and the main starting material for arsenic chemistry. It appears as odorless, tasteless and 
white crystals or powders (Fig 1.7). The structure of AS2O3 is a ring shape with formula 
AS4O6 (Gorby, 1994) (Fig 1.8). In traditional Chinese medicine, it is called pishuang (石比 
霜).It can be prepared by purifying from a naturally occurring complex called pishi (石比 
石)which composed 90% of AS2O3 (Fig 1.7)(中医药发展筹备委员会，1997). 
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Fig 1.7 The appearance of AS2O3 and pishi 
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Fig 1.8 The structure of AS2O3 
Arsenic is ubiquitous in the natural environment. Arsenic trioxide is one of the 
arsenites, the inorganic forms of arsenic in the trivalent state As^^ found in nature and is 
produced mainly from products of copper smelting. 
In the past, Arsenic is considered to be toxic drugs, so its primarily application is 
used for wood preservatives, insecticides, and herbicides. It is also used in metallurgical 
processes, and in the manufacturing of glass and ceramics. 
Arsenic compounds were formerly used medicinally in humans in both Western and 
Chinese societies in treating some severe diseases. In Western medicine, AS2O3 was 
prepared to the Fowler's solution to treat hemorrhoids, acute ulcerative gingivitis and 
asthma externally. And in Chinese society, AS2O3 also has been used for many decades 
in traditional Chinese medicines for treatment of various human diseases like ulcer and 
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asthma (Shen at cd,, 1997). 
1.5.2 The Medical use of Arsenic Trioxide (AS2O3) 
Arsenic has been used as a therapeutic agent for more than 2400 years in different 
part of the world. In 15th century, discovered by William Withering, AS2O3 was used to 
treat digitalis (Aronson, 1994). In 18th century, Thomas Fowler compounded a 
portassium bicarbonate-based solution of AS2O3 named Fowler's Solution for the 
treatment of a variety of disease until early 20th century. As early as in 19th century 
Fowler's solution was used as a treatment of choice for chronic myeloid leukemia (CML). 
However, due to toxic side effects of long-term heroic-dose of oral arsenic in most 
patients, and with the advent of modem radiotherapy and chemotherapy, the arsenic 
treatment for C M L was given up in Western medicine (Kwong and Todd, 1997, Tamm et 
al., 1998). 
As in traditional Chinese medicine, the medical application of AS2O3 was found in 
the Compendium of Materia Medica by Mr Li Shi-Zhen 李时珍(1518 一 1593) ( Zhang et 
al； 2001). It was used to treat skin diseases and asthma (Wang et al., 2001). However, 
AS2O3 was considered as a poison for a long time. In early 1970s, a discovery from China 
revived this drug. A group of researchers from Harbin Medical University in Northeast 
China found that intravenous administration of arsenic trioxide (AS2O3) with relatively 
small doses (10 mg/d) was effective in treating patients with APL, lymphoma, and liver 
cancer (Zhang, 1988, Li et al., 1988, Sun et al., 1992). Then, in 1992, Sun et al reported 
promising results of 32 cases of APL treated with AS2O3 (Sun et al” 1992). Later, a trial 
performed at the Shanghai Second Medical University indicated that complete remission 
(CR) could be achieved in 14 of 15 investigated patients that had relapsed after prior 
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treatment with all-trans retinoic acid (ATRA) or conventional chemotherapy (Shen et al., 
1997). In the Western, the population clinical efficacy of AS2O3 was proved by studies 
performed by Soignet et al (Soignet et al., 1998, Soignet et al., 1999). Recently, the drug 
(TrisenoxTM) was formally approved by the State Food and Drug Administration (SFDA) 
in China (1999) and the Food and Drug Administration (FDA) of the United States of 
America (2000). 
1.5.3 Arsenic Trioxide (AS2O3) in treating Acute Promyelocytic 
Leukemia (APL) 
1.5.3.1 Acute Promyelocytic Leukemia (APL) 
Acute promyelocytic leukemia (APL or AML-M3 and M3-variant) represents a 
unique model for cancer research in terms of the biological and clinical features. It has 
been shown during the last decade that PML-RARa chimeric protein, as a result of the 
specific chromosome translocation t(15; 17), plays a central role in APL pathogenesis 
(Chen et al., 1997). APL is characterized by chromosomal translocation involving the 
retinoic acid receptor-alpha gene on chromosome 17 (RARa). In 95% of APL cases, 
retinoic acid receptor-alpha (RARa) gene on chromosome 17 is involved in a reciprocal 
translocation with the promyelocytic leukemia gene (PML) on chromosome 15，a 
translocation denoted as t(15;17)(q22;ql2). Four other gene rearrangements including 
fusing RARa to promyelocytic leukemia zinc finger (PLZF), nucleophosmin (NPM), 
nuclear matrix associated (NUMA), or signal transducer and activator of transcription 5b 
(STAT5B) genes have been described in APL. The resultant fusion proteins disrupt the 
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function of R A R a which blocks the normal maturation of granulocytes. Although the 
chromosomal translocation involving "RARa" is believed to be the initiating event, 
additional mutations are required for the development of leukemia (Kumar et al., 2004). 
1.5.3.2 All-trans Retinoic Acid (ATRA) Treatment of A P L 
Before the 1990s, patients with APL were treated with anthracyclines combined with 
cytosine arabinoside (Bernard et al., 1973). In the First reports of A T R A therapy 
published by the research groups in Shanghai and other countries, C R rates of about 90% 
were reported in newly diagnosed and first relapse APL patients treated with a dose of 45 
mg/m2 daily A T R A (Huang et al., 1988, Castaigne et al., 1990, Degos et al., 1990, Chen 
et al., 1991，Warrel et al., 1991). The in vitro and in vivo studies indicated that A T R A 
induced a terminal differentiation followed by a natural apoptosis of malignant cells and 
is, thus, the leading drug for modifying the biological process of malignant cells, so it 
was effective essentially in the leukemia-bearing specific chromosome aberration t(15;17) 
with P M L 士 R A R a fusion gene. The treatment of APL with A T R A constitutes a 
successful model for gene-targeting therapy (Degos and Wang, 2001). 
Although the A T R A is found to cause an increase in C R rate, some adverse effects 
also found during or after treatment. In 30% of the patients treated with A T R A as a 
single drug was associated with rapid increase in leukocytes and signs of "ATRA 
syndrome", which could have fatal outcome (De Botton et al., 1998). And following 
treatment with A T R A alone, patients experienced an induction of a secondary resistance 
to ATRA. Secondary resistance occurs in all patients treated with A T R A (Warrell et al., 
1994). Thus, patients receiving A T R A alone achieved C R for only a short time, usually 
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relapsing within 6 months. Patients treated with A T R A become refractory to this 
treatment for a period of 6 - 12 months and the acquired resistance is usually reversible 
after this period (Degos and Wang, 2001). These side effects promote the scientists to 
modify the treatment of APL. 
1.5.3.3 Clinical Trial of the Arsenic Trioxide on A P L 
Since the A T R A has the adverse effects mentioned above, scientists started to 
modify the treatment. Based on the principle in Chinese traditional medicine of "use a 
toxic agent against a toxic agent," in the early 1970s a group of clinical researchers at 
Harbin Medical University began to treat some types of cancer with white arsenic, which 
is known to be a toxin. Encouraging results have been observed in the treatment of 
esophageal carcinoma, malignant lymphoma, and leukemia, particularly C M L and acute 
promyelocytic leukemia (APL) (Wang, 2001). Then clinical trials were done by research 
groups in Chinese and western countries in the following years. (Shown in Table 1.1) 
Generally arsenic trioxide achieved complete remission (CR) rate of 57-98% in APL 
patients. (Zhang et al., 2001) 
1.5.3.4 In vitro and in vivo Study of Arsenic Trioxide (AS2O3) in treating 
APL 
After 1970s when AS2O3 were found to be effect in treating APL patients, the action 
mechanism studies of AS2O3 were followed. NB4 cells, an APL cell line with 
chromosome translocation t(15:17) from a relapsed APL patient were used in the in vitro 
study. AS2O3 was found to have a dose-dependent dual effect: inducing preferentially 
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apoptosis at relatively high concentrations (0.5 to 2 mmol/L) and inducing partial, 
differentiation at low concentrations (0.1 to 0.5 mmol/L) (Chen et al., 1997). On one 
hand, in high concentrations, AS2O3 induced apoptosis in APL. The most important 
mechanism is degradation of the APL-specific PML/RARa fusion transcript. AS2O3 
induced a significant modulation of the P M L staining pattern in NB4 cells and HL-60 
cells (Chen et al., 1996, Shao et al； 1998). The characteristics ofPML-RARa in N B cells 
disappear after treatment with AS2O3, whereas a diffuse P M L staining occurs in the 
perinuclear cytoplasmic region. Other mechanism reported include induction of apoptosis 
through modulate effects on pro-and anti-apoptotic molecules such as bax, bcl-2 gene 
expression at both m R N A and protein levels (Chen et al., 1996, Kinjo et al, 2000). In 
addition, AS2O3 induced apoptosis by enhancing the reactive oxygen species (ROS) 
content and the activity of caspase 3 in NB4 cells, thus damaging the mitochondrial 
membrane (Wang, 2001). Further study also indicated that AS2O3 induces apoptosis 
without differentiation in retinoic acid-sensitive and retinoic acid resistant APL cells at 
concentrations that are achievable in patients (Shao et al., 1998, Kinjo et al, 2000). 
On the other hand, in vitro and in vivo experiments have demonstrated that low-dose 
AS2O3 induces differentiation of NB4 cells as well as fresh APL cells. The differentiation 
is characterized by maturation of morphology, elevation of cytoplasmic-nuclear ratio. 
Condensation of chromatin structure, appearance of neutrophilic granules, increased 
expression of CD lib and adhesion molecules and decreased expression of CD33 (Chen 
et al., 2001). AS2O3 could induce degradation of both PML-RARa fusion protein and 
wild-type P M L protein in APL cells. These, together with the fact that AS2O3 could not 
induce the degradation of PLZF-RARa, suggest P M L moiety is the target of AS2O3. 
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AS2O3-induced degradation was also associated with the distribution of P M L proteins to 
nuclear matrix and the conjugation with a ubiquitin-related protein SUMO-1 (Stemsdorf 
et al., 1999). Further investigation showed the upregulation of CD52 and BFl-1, 
downregulation of R A R a and synergistic effects in regulation of protein kinase CB-1 
(Cai et al., 2000). Recent findings showed that arsenic trioxide induces acetylation of 
histories 3, 4 resulting in transcriptional activation of downstream genes for 
differentiation (Fang et al., 2002). 
1.5.3.5 C o m m o n Side Effects of Arsenic Trioxide (AS2O3) on A P L 
Of course, known as a poison for many centuries, AS2O3 causes multiple adverse 
effects during treating APL, including hyperglycemia, dyspnea, QT prolongation, torsade 
de pointes tachycardias (TdP), sudden cardiac death, fatal APL differentiating syndrome 
(characterized by fever, dyspnea, weight gain, pulmonary infiltrates and pleural or 
pericardial effusions, with or without leukocytosis) (St. Petery et al., 1970; Shen et al., 
1997, Ohnishi et al., 2000; Unnikrishnan et al., 2001; Westervelt et al., 2001). However, 
treatment with AS2O3 was not associated with significant B M suppression-no significant 
changes of hemoglobin (Hb) and platelet levels were observed in patients. Arsenic 
trioxide treatment does not cause hair loss，mouth sores and doesn't significantly lower 
blood counts like other chemotherapy. Moreover, although about 40% percent of patients 
experienced a QT prolongation in AS2O3 treatment with APL, almost all of them 
recovered after the treatment were stopped. The patients' electrocardiograms (ECG) need 
to be closely monitored during treatment. Therefore, according to the report by Shen et al 
in 1997, Clinical observations revealed that the currently used dose (10 mg) of AS2O3 
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through administration resulted in only mild to moderate side effects (Shen et al., 1997). 
Table 1.1 Summary of clinical trials of arsenic trioxide (AS2O3) on APL patients 
(Wang, 2001) 
「 ‘ CRrate 
Year Compound of Reference 
patients 。 
- Ailing-1 严 32 85.5 Sun etal, 1992 
1995 Composite Indigo 60 98 ^1998 ^ ^ ' 
1996 AS2O3 30 I 73.3 Zhang et al, 
I 1996 
— 1 9 9 6 —…——AS203 42 52.4 ‘ 
1997 Ailing-1 15 ( 93 Shen et al1997 
—]998— 「 — i T 9 2 — — 
— " " “ “ ^ 87.1 广 M a etal, 1998 
^ ----- 丁—一一11 72.7 ' � Nil! et al” 1999 
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1.5.4 Anti-cancer effect of Arsenic Trioxide on other cancers 
Apart from APL, AS2O3 inhibits growth and promotes apoptosis in other 
hematological cancer cell lines. 
Zhang et al. have reported that at a concentration of 1 jiM, AS2O3 markedly inhibits 
both proliferation and viability of NB4 cells, myeloma NOP-1 cells, lymphoma NOL-3 
cells, myeloid NKM-1 cells, normal peripheral blood lymphocytes (PBLs), non-Hodgkin's 
lymphoma (NHL) cells, and chronic lymphocytic leukemia (CLL) cells (Zhang et al., 
1998). In 1999, Studies performed by Zhu et al. have revealed that AS2O3 markedly 
inhibits growth in a dose- and time-dependent manner in eight lymphoproliferative 
disease cell lines: Nalm-6; Namalwa and Raji; BJAB; Su-DHL-4; Molt-4 Jurkat; and 
SKW-3. It induced apoptosis only in Nalm-6, Namalwa, Raji, Su-DHL-4, and Jurkat cells. 
The apoptosis induced by AS2O3 is associated with disruption of mitochondria 
trasmembrance potential (Avj/m) and caspase 3 activation. Degradation of P M L protein 
also occured, and there were no alterations in c-myc, Rb, CDK4, cyclin Dl, pl6, and p53 
(Zhu et al., 1999). Arsenic trioxide also inhibited proliferation in K562 cells by inducing 
G2/M phase cell cycle and upregulating Survivin m R N A expression and content of 
Survivin protein (Wu et al., 2004). 
AS2O3 also has anti-proliferation effect and induce apoptosis on solid tumors such as 
prostate cancer, renal cancer, cervical cancer, hepatoma, breast cancer and so on. Lin C et 
al. reported AS2O3 induced G2+M arrest of tumor cells such as GLC-82, MGC-803, 
SGC-7901, Ecal09 and HeLa cells before induced apoptosis and decreased c-myc gene 
expression, whereas caused G1 block of HPV16 D N A immortalized cervical epithelial 
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HCE16/3 cells and did not affect c-myc expression (Lin et al., 2000). Park et al, reported 
Arsenic trioxide inhibited the proliferation of renal cell carcinoma cell lines (ACHN, 
A498, Caki-2, Cos-7, and Renca) by inducing a Gl or a G2-M phase arrest in these cells. 
And it decreased the levels of CDK2, C D K 6, cyclin Dl, cyclin E, and cyclin A proteins 
in A498 cells. And apoptotic process of A498 cells was associate with Bcl-xl, caspase 9, 
caspase 3, and caspase 7 proteins as with as Avj/m loss (Park et al., 2003). Shao et al 
reported that AS2O3 induced dose-dependent apoptosis in gastric carcinoma cells, 
M K N 4 5 cells, blocked at G2/M phase (Shao et al., 2005). Chan et al reported AS2O3 was 
effective in inhibiting the cell proliferation of R-HepG2 cells in a dose- and time-
dependent manner via induction of apoptosis without affecting the cells cycle (Chan et al,, 
2006). And Li X et al reported that arsenic trioxide cause redistribution of cell cycle, 
caspase activation, and G A D D expression in human colonic (HT-29), breast (MCF-7) 
and Pancreatic (AsPC-1) cancer cells (Li et al., 2004). 
1.6 Aim of the Study 
This study investigates the effects of AS2O3 on human breast tumor cell lines, MCF-
7 (Fig 1.9) and MDA-MB-231 (Fig 1.10). MCF-7 cells are estrogen receptor (ER) a 
positive whereas MDA-MB-231 cells are estrogen receptor ERa negative, mimicking the 
two classes of breast cancer. 
The aim of this study is to (1) explore the potential anti-cancer effect of AS2O3 on 
MDA-MB-231 cells; (2) the action mechanisms of AS2O3 on MDA-MB-231 cells (3) in 
vivo study of anti-tumor effect of AS2O3 in breast cancer. 
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ATCC Number: HTB-22 
Designation: MCF-7 
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Fig 1.9 MCF-7 cells from ATCC 
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Fig 1.10 MDA-MB-231 cells from ATCC 
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Chapter 2 
Materials and Methods 
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2.1 Materials 
2.1.1 Cell Lines and Culture Medium 
2.1.1.1 Cell Lines 
MCF-7 and MDA-MB-231 cell lines were purchased from American Type Culture 
Collection (ATCC, Rockville, M D , USA). Both cell lines were maintained in complete 
RPMI 1640 medium (Invitrogen, USA), which was supplemented with 10% fetal bovine 
serum (v/v, FBS, Invitrogen, USA) and 1% penicillin-streptomycin (v/v, PS, 10 OOOU/ml, 
Invitrogen, USA). The cells were maintained at 37°C in a humidified atmosphere of 5% 
carbon dioxide (CO2). Cells were cultured in 150cm culture flask (IWAKI) and were 
sub-cultured twice a week. 184B5 cell was purchased from American Type Culture 
Collection (ATCC, Rockville, M D , USA). Cells were cultured in complete mammary 
epithelial cell growth medium (MEGM; Clonetics) supplemented with M E G M bullet kit 
(Clonetics), which contains EGF, insulin, hydrocortisone, bovine pituitary extract, 10 
ng/mL hEGF, 5 |ag/mL insulin, 0.5 |ig/mL hydrocortisone, 50 |ig/mL gentamicine, and 52 
|ig/mL bovine pituitary extract at 37 in a humidified atmosphere of 5% CO2. The cells 
were cultured in 150cm^ and were sub-cultured twice a week. 
2.1.1.2 Culture Media 
Roswell Park Memorial Institute Tissue Culture Medium 1640 (RPMI 1640 
Medium, Introgen, USA) 
RPMI 1640 medium was prepared by dissolving the powder containing phenol red, L-
glutamine and 0.5mM HEPES in IL of dHzO. The medium was supplemented with 2g of 
NaHCOs every 5L. The pH was adjusted to 7.2. The medium was then filtered by 0.22}xm 
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bottle-top filter (Millipore). The complete RPMI 1640 medium was supplemented with 
10% fetal bovine serum (v/v, FBS, Invitrogen, USA) and 1% penicillin-streptomycin (v/v, 
PS, lOOOOU/ml, Invitrogen, USA). The media were stored at 4°C. 
Mammary Epithelial Cell Growth Medium (MEGM; Clonetics CA, USA) 
The complete M E G M medium was supplemented EGF, insulin, hydrocortisone, bovine 
pituitary extract. lOng/mL hEGF, 5jig/mL insulin, 0.5|Lig/mL hydrocortisone, 50)ig/mL 
gentamicine, and 52}ig/mL bovine pituitary extract. The media were stored at 4 
2.1.2 Chemicals 
Arsenic Trioxide (AS2O3) was purchased from Sigma Chemical Company. It was 
prepared by dissolving powder AS2O3 in boiled phosphate buffered saline (PBS) in 
lOmM. Boiling was continued until AS2O3 powder was completely dissolved. Distilled 
water was added to compensate the loss of water vapor during boiling. The stock solution 
was sterilized by using 0.22|iM filter (Millipore) and stored at -20 Aliquots of lOmM 
were prepared for in vitro studies, which was further diluted to working concentration 
with culture medium. 
Tamoxifen was purchased from Sigma Chemical Company. Stock solution of 10 |iM was 
freshly prepared by dissolving in absolute ethanol and sterilized with 0.22^M filter 
(Millipore). Working solutions with various concentrations was prepared with culture 
medium for in vitro culture. 
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17-estradiol 60-day Release Pellets were purchase form Innovative Research of 
America. Each pellet contains 0.72mg 17-estradiol with biodegradable carrier-binder. 
The pellets were stored at room temperature for in vivo study use. 
2.1.3 Buffers and Reagents 
Trypsin-EDTA Solution 
Trypsin-EDTA solution, containing 0.25% Trypsin and 1 m M EDTA-tetrasodium in 
HBSS without Ca and M g , was purchased from Invitrogen, USA. 
Trypan Blue Solution 
Trypan blue solution was purchased from Sigma Chemical Co. It contained 0.4% (w/v) 
trypan blue dissolved in 0.817% (w/v) NaCl and 0.06% (w/v) K2PO4. 
lOx Tris-Glycine 
lOx Tris-glycine was prepared by dissolving 30.3g Tris and 144g glycine in IL dHiO. 
The pH was adjusted to 8.3 and was stored at 4°C 
Normal Saline: 0.9% (w/v) Sodium Chloride (NaCl) 
0.9% NaCl was prepared by dissolving 9g of solid form of NaCl in IL of dH20 at room 
temperature. 
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Phosphate Buffered Saline (PBS) 
PBS was prepared by mixing 136mM NaCl, 2.7mM KCl, L 5 m M KH2PO4 and 8 m M 
Na2P04. The chemicals are dissolved in ddH20. The pH was adjusted to 7.4, the solution 
was sterilized by autoclaving, stored at room temperature. 
Tris Buffered Saline (TBS) 
TBS was prepared by dissolving 12.114g Tris and 87.66g NaCl in IL dH20. The pH was 
adjusted to 8 and stored at 4。C. 
Tris-acetate (TAE) Buffer 
TAE was prepared as 5Ox concentrated stock solution by dissolving 242g Tris base, 
57.1ml glacial acetic acid and 100ml 0.5M E D T A (pH 8.0) in IL dHzO. 
Tris-EDTA (TE) Buffer 
TE was prepared by mixing lOmM Tris-Cl and I m M E D T A in dH20. The pH was 
adjusted to 7.4. 
2.1.4 Reagents for MTT Assay 
Tetrazolium Salt 3-(4, 5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
(MTT, Sigma) Solution 
M T T was prepared by dissolving it in PBS at concentration of 5mg/mL The solution was 
then filtered by a 0.22^m filter (Millipore) and stored at 4°C in dark. 
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2.1.5 Reagents for DNA Fragmentation Assay 
2.1.5.1 Reagents for D N A Extraction 
DNA Lysis Buffer 
Lysis buffer was prepared by mixing 200mM Tris-HCL buffer (pH 8.3), lOOmM E D T A 
and 1% SDS (w/v) in PBS. It was stored at room temperature. 
Proteinase K 
Proteinase K was purchased from Sigma chemical Co. It was dissolved in PBS. It was 
stored at -20 °C 
Ribonuclease A (RNase A) 
Ribonuclease A (RNase A) was purchased from Sigma Chemical Co. It was dissolved in 
TE buffer (5mg/ml, pH 7.4) and stored at -20°C 
2.1.5.2 Reagents for Gel Electrophoresis 
1.5% Agarose Gel (w/v) 
1.5% agarose gel was prepared by dissolving 0.75 agarose (Sigma Chemical Co.) in 50ml 
TAE. It was boiled until the agarose was melted. The gel was cooled down to about 50"C 
and 5|j.l of ethidium bromide (EtBr) (Amersham Biosciences Ltd.) was added. It was then 
poured into a cast gel system. 
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6x DNA Loading Dye 
6x D N A loading dye was prepared by mixing 0.25% (v/v) bromophenol blue, 0.25% (v/v) 
xylene cyanol FF and 30% (v/v) glycerol in dH�。. 
DNA Marker 
100 Base-Pair D N A Marker was prepared by mixing 3|LI1 of 1 |ig/|il of the 100 base-pair 
D N A marker (Amersham Biosciences Ltd.), 4|li1 of 6x D N A loading dye and 5[l\ 
autoclaved dH20. 
2.1.6 Reagents and Chemicals for Western Blotting 
2.1.6.1 Reagents for Protein Extraction 
Protein Lysis Buffer 
Lysis buffer was prepared by mixing 21|Lig/ml aprotinin, 5|Lig/ml leupeptin, 5 m M MgCh, 
I m M phenylmethylsulfonylfluoride (PMSF), 1% (w/v) SDS, I m M sodium meta-
vanadate (NasVCU) and lOmM Tris buffer (pH 7.4) in PBS, stored at room temperature. 
Protein Standard (2mg/ml) 
Protein standard was prepared by dissolving 0.004g bovine serum albumin (BSA) in 2ml 
dH20. It was stored at - 2 0 . 
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Bicinchoninic acid (BCA) solution (Reagent A) 
B C A solution was purchased from Sigma Chemical Co. and was stored at room 
temperature. 
ReagentB 
Reagent B was prepared by dissolving 4g of CUSO4 5H2O in 100ml dH20. It was stored 
at room temperature. Mixture of B C A solution and reagent B should be freshly prepared 
each time. 
2.1.6.2 Reagents for SDS-PAGE 
10% Ammonium Persulfate (APS) 
APS was prepared by dissolving Ig ammonium persulfate powder in 10ml dH20. It was 
stored at -20 °C. 
4x Lower Gel Buffer 
4x lower gel buffer was prepared by dissolving 181.6g Tris and 4g SDS in IL of dHzO. 
The pH was adjusted to 8.8 and it was stored at room temperature. 
4x Upper Gel Buffer 
4x upper gel buffer was prepared by dissolving 60.6g Tris and 4g SDS in IL of dH�。. 
The pH was adjusted to 8.8 and it was stored at room temperature. 
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12.5% Separating Gel for SDS-PAGE 
12.5% separating gel was prepared by mixing 1.0825 ml of dHzO, 1.6675 ml of 30% 
acrylamide, 1ml of 4X upper gel buffer, 4.65iil of N, N, N，，N'-tetrameyhyl-ethylene 
diamine (TEMED) and 20)11 of 10% APS. Mixture should be freshly prepared for each 
experiment. 
4.5% Stacking Gel for SDS-PAGE 
4.5% stacking gel was prepared by mixing 1.2ml of 邮 0 , 0.3ml of 30% acrylamide, 
0.5ml 4X lower gel buffer, 2.65|al of T E M E D and 15|LI1 of 10% APS. Mixture should be 
freshly prepared for each experiment. 
2x SDS Loading Dye 
2x SDS loading dye was prepared by dissolving 2 % (w/v) SDS, 10% sucrose, 0.002% 
bromophenol blue and 62.5mM Tris in dH20. The pH was adjusted to 6.8. Then the 
loading buffer was supplemented with 5% (v/v) 2-mercaptoethanol and stored at 4°C. 
lOx SDS Running Buffer 
lOx SDS running buffer was prepared by dissolving 30.3g Tris, 144g glycine and lOg 
SDS in lLofdH20. 
R a i n b o w ™ Coloured Protein Molecular Weight Marker 
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RainbowTM coloured protein molecular weight marker was purchased from Amersham 
Biosciences Ltd. 
Polyvinylidene Difluoride (PVDF) Western Blotting Membrane 
PVDF membrane with a pore size of 0.45 |Lim was purchased from Millipore Corporation. 
Electroblotting Buffer 
Electroblotting buffer was prepared by mixing 66.7ml of lOx Tris-glycine, 100ml 
methanol and 500ml of dHaO. 
Tris-Buffered Saline with 0.1% Tween-20 (TBS-T) 
Tris-Buffered Saline with 0.1% Tween-20 (TEST) was prepared by mixing 1ml of 
Tween-20 in IL TBS. 
Blocking Solution 
Blocking solution was prepared by dissolving Ig of non-fat milk powder in 10ml of 
TEST. It was stored at4°C. 
Primary and Secondary Antibodies 
The primary antibodies included mouse monoclonal anti-human P-actin (Sigma), mouse 
monoclonal anti-human bcl-2(Santa Cruz Biotechnology Inc), mouse monoclonal anti-
human bax (Santa Cruz Biotechnology Inc), mouse monoclonal anti-human caspase 9 
(Stressgen), rabbit polyclonal anti-human cytochrome c (Santa Cruz Biotechnology Inc), 
rabbit polyclonal anti-human FasL (Santa Cruz Biotechnology Inc), mouse monoclonal 
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anti-human caspase 8 (BD Biosciences), mouse monoclonal anti-human caspase 3 (Santa 
Cruz Biotechnology Inc), rabbit polyclonal anti-human PARP (Santa Cruz Biotechnology 
Inc), mouse monoclonal anti-human p53 (Santa Cruz Biotechnology Inc), Rabbit 
monoclonal anti-human cyclin B1 (Abeam) and mouse monoclonal anti-human cyclin 
E(BD Biosciences). They were stored at -20°C. The secondary antibodies included goat 
anti-mouse IgG and goat anti-rabbit IgG HRP were purchased from Pharmigen and Santa 
Cruz Biotechnology Inc. respectively. They were stored at 4°C. 
Enhanced Chemiluminescence (ECL) Assay 
Enhanced chemiluminescence (ECL) assay kit was purchased from Amersham 
Biosciences Ltd. It was stored at 4°C. 
2.1.7 Reagents for Flow Cytometry 
BD Pharmingen™ Annexin V Kits (Bio-Gene Technology Ltd.) 
B D PharmingenTM Kits was purchased from Bio-Gene Technology Ltd. The kit contains 
Annexin V-FITC, lOxBinding Buffer and Propidium Iodide. It was stored at 4°C. 
Propidium Iodide (PI) 
Propidium iodide was purchased from Sigma Chemical Co. It was reconstituted in PBS 
(2mg/ml). 
Ribonuclease A (RNase A) 
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Ribonuclease A (RNase A) was purchased from Sigma Chemical Co. It was dissolved in 
TE buffer (5mg/ml, pH 7.4). 
2.1.8 7/1 Vivo Study 
Animal Model: Balb/c Nude Mice 
Female Balb/c nude mice aged 4-6 weeks were used as animal models for in vivo study. 
The mice were bred at the Laboratory Animal Services Center of The Chinese University 
of Hong Kong under pathogen-free condition in air-controlled rooms.. 
Sodium Pentobarbital Solution 
Sodium pentobarbital solution was prepared by dissolving 25mg of sodium pentobarbital 
in 1 ml of sterile PBS. It was stored at 4°C. 
Heparin Solution 
Heparin solution was prepared by dissolving 50 units of heparin in 1 ml of sterile PBS. It 
was stored at 4。C. 
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2.2 Methods 
2.2.1 Cell Treatment 
Cells were incubated with RPMI 1640 or M E G M medium for 24 hours at 37 "C, 5% 
CO2 and then the medium was discarded and AS2O3 was added with fresh medium for 24, 
48 and 72 hours. 
2.2.2 Trypan Blue Exclusion Assay 
O.40/0 trypan blue solution was mixed with lOjil of cell suspension. Then, 10|il of the 
solution was transferred to the hemacytometer. The viable cells, which were un-stained, 
were counted in a square of hemacytometer. The cell concentration (cells/ml) was 
calculated as follows: 
Cells per ml = number of cell x lO^x dilution factor 
2.2.3 MTT assay 
1x104 cells per well were seeded onto a 96-well plate in lOOjiil RMPI 1640 or 
M E G M medium at 37°C, 5% CO2. After 24 hours, medium was removed. Cells were 
treated with different concentrations of AS2O3 or other drugs in a fresh medium. After 24， 
48 or 72 hours, the medium in each well was removed and each well was washed with 
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PBS. Untreated control was prepared by treating cells in the medium only. Then, 30|xl of 
M T T solution (5mg/ml) was added to each well and the plate was incubated at 37°C for 3 
hours. After the incubation, the M T T was discarded and 100|xl D M S O was added to 
dissolve the crystals in the cells and the culture was further incubated for 30 minutes at 
room temperature. D M S O (100|j,l) was used as blank. The absorbance at 540nm was 
measured using an ELISA plate reader (BIO-RAD). 
Percentage survival of each sample was expressed using the following formula mean 
士 standard deviation (S.D.): 
% Survival = 100% x (O.D. test sample/ O.D. control) 
2.2.4 Detection of DNA Fragmentation 
5x10^ cells per well were seeded onto 60mm culture dish in 5ml RPMI 1640 
medium and incubated at 37°C, 5% CO2. After the treatment, cells were lysed with 400 |xl 
of D N A lysis buffer and vortexed until no cell debris was left. Twenty microliter of 10 
mg/ml proteinase K was added and incubated at 37° for at least 2 hours. Then, 150|il of 
saturated NaCl was added, the sample was shake vigorously. The mixture was 
centrifuged at 6500xg for 15 minutes. The supernatant was collected, 1 ml of cold 
ethanol was added and centrifuge again at ISOOOxg for 20 minutes. After rinsed with cold 
75% ethanol, the pellet was dried at room temperature. Finally, 20|LI1 of 0.2mg/ml RNase 
A in Tris-EDTA buffer was added to each sample and further incubated at 37°Cfor 90 
minutes. Equal amount of sample was electrophoresed in 1.5% agarose gel and visualized 
by ethidium bromide staining. 
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2.2.6 Flow Cytometry 
2.2.5.1 Detection of Cell Cycle Pattern with PI 
3x10^ cells per well were seeded onto 6-well plate in 3ml RPMI 1640 medium and 
incubated at 37°C, 5% CO2. Twenty four hours later, medium was discarded and AS2O3 in 
fresh medium was added. Then after 72 hours, cells were harvested and washed with PBS. 
Cells were then fixed with 1 ml of 70% ethanol at 4°C overnight. After fixation, the cells 
were centrifliged at 3000xg for 5 minutes to remove the ethanol. Cells were then 
resuspended in 0.46 ml freshly prepared propidium iodide solution containing propidium 
iodide (43 ^ ig/ml) and RNase A (Img/ml) and incubated in dark at 37°C for 30 minutes. 
After incubation, the cells were analyzed by FAC Sort flow cytometer (Becton Dickinson). 
2.2.5.2 Detection of Apoptosis with Annexin V-PI 
The detection of apoptosis was performed by using B D Pharmingen™ Annexin V-
FITC kit (Bio-Gene Technology Ltd.). 5x10^ cells were seeded in a 60 m m culture dish. 
24 hours later, medium was discarded and AS2O3 was added with fresh medium. Then 
after 72 hours, cells were harvested and washed with PBS. 1x10^ cells were used for the 
assay. 10)LI1 of lOx binding buffer, lOjil of PI, 3^1 of Annexin V-FITC conjugate and 77|il 
of dH20 were added to a sample and incubated in the dark at room temperature for 15 
minutes. After incubation, 400jal of Ix binding buffer was added to the sample and the 
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sample was analyzed by FACSort flow cytometer (Becton Dickinson) as soon as possible. 
A computer program, WinMDI, was used for data analysis. 
2.2.6 Western Blot Analysis 
2.2.6.1 Protein Extraction 
1x106 cells were seeded on 100mm culture dish with 10ml RPMI 1640 medium. 24 
hours later, AS2O3 in the medium was added. Seventy two hours later, cells were 
collected and washed twice with PBS. 100|il of lysis buffer was added and allowed to 
stand on ice for at least 2 hours. Then, samples were boiled for 10 minutes and 
centrifuged at 13600xg for 10 minutes at 4°°C. Finally, the supernatant was collected and 
stored at : - 20°C. 
2.2.6.2 Protein Concentration Determination 
The protein concentration was determined by bicinchoninic acid (BCA) protein assay. 
One microliter of each sample was mixed with 9|il of dH20 in a 96-well plate. Bovine 
serum albumin (BSA) was used to draw the protein standard curve. Each sample and 
BSA standard was done in triplicate. B C A reaction mixture contained B C A solution and 
reagent B in the ratio of 50 i 1. 200|il of B C A mixture was added to each well and 
incubated at 37 "C for 30 minutes. After incubation, the absorbance at 540 nm was 
measured by ELISA plate reader (Bio-Rad). Standard curve of protein amount was 
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plotted against the OD540nm (Fig. 2.1), and the amount of protein in the sample was 
calculated accordingly. 
2.2.6.3 Western Blotting 
SDS-PAGE 
An apparatus of 3D vertical electrophoresis system (Bio-Rad) was assessed 
according to manufacturer's manual. Polyacrylamide separating gel (12.5%) was 
prepared with 1.0825 ml of dH20, 1.6675 ml of 30% acrylamide, 1ml of 4xupper gel 
buffer, 4.65|il ofTEMED and 20^1 of 10% APS. 4.5% stacking gel was set with 1.2ml of 
dH20, 0.3ml of 30% acrylamide, 0.5ml 4x lower gel buffer, 2.65j^ l o f T E M E D and 
of 10% APS. 
According to the BSA standard curve, equal amount of protein samples (25-
40|Lig) were used for SDS-PAGE. Protein samples were mixed with equal volume of 2 x 
SDS loading dye and boiled for 10 minutes. The samples were loaded to the well of the 
polyacrylamide gel with rainbow coloured protein molecular marker (Amersham 
Bioscience Ltd.), and run at 120V for 90 minutes. 
Transfer of Protein to PVDF Membrane by Electroblotting 
Semi-Dry Electrophoretic Transfer Cell (semi-dry blotter, BioRad) was assessed 
according to the protocol as the manufacturer's manual. 0.45|im PVDF membrane 
(Millipore) was used for electroblotting. The dry PVDF membrane was soaked in 100% 
methanol for re-hydration. The membrane was then put in E-blot buffer for several 
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seconds. Three pieces of Whatman 3 m m papers were soaked in E-Blot buffer and put 
onto the platinum anode. The membrane was put onto the Whatman 3 m m papers and the 
gel was put onto the membrane. Another 3 pieces of E-blot buffer-soaked 3 m m paper 
were then put onto the gel. The proteins were transferred at constant current at 0.15A for 
2 gels for 60 minutes. 
Probing Proteins with Antibodies 
After transfer of protein to the PVDF membrane, the membrane was blocked with 
10% non-fat milk (in TBS-T) at room temperature for 2 hours. Then, it was washed with 
TBS-T for 15 minutes for 3 times. Primary antibody, 0.6|al of mouse anti-human P-actin 
(as an example) in 3ml 10% non-fat milk was added for probing at room temperature for 
2 hours. After probing, the membrane was washed with TBS-T for 10 minutes for 3 times 
and probed with secondary antibody (conjugated with horseradish peroxidase) at room 
temperature for 1 hour. The membrane was washed again with TBS-T for 10 minutes for 
3 times and it was ready for ECL detection. 
Enhanced Chemiluminescence (ECL) Assay 
ECL assay was used for detection of probed proteins. ECL detection reagent 1 and 
reagent 2 (Amersham) were mixed in the ratio of 1:1 and the membrane was immersed in 
the mixture for 90 seconds. Then the membrane was wrapped and put into the 
Hypersensitive film cassette (Amersham) followed by a Fuji Medical x-ray film (Super 
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Rx, Fuji) in dark with various exposure time. The film was then developed by a film 
processor (M35 X-OMAT, Kodak). 
2.2.7 In Vivo Study 
2.2.7.1 Animal Model 
Female nude mice as 4-6 week old were used for investigating the in vivo effect of 
AS2O3 against breast cancer. The animals were housed under specific pathogen-free 
conditions in air-controlled rooms, which were specifically designed for maintenance of 
nude mice. Mice were fed with chow and sterile water ad lib in a 12-h light/dark cycle. 
To support the growth of the estrogen-dependent MCR-7 tumor, a 0.72-mg 17-P estradiol 
60-day release pellet was implanted subcutaneously (5.c). Ten days before pellet 
inculation, 1x10? cells were inoculated s.c. into the anterior part of the nude mice and 
allowed to grow for 5-10 days. The weights of the mice, size of tumor were measured 
before the treatment. Treatments were started when the tumor size reached about 50mm^ 
2.2.7.2 Treatment Schedule 
The mice were divided into 3 groups, 7 mice per group, randomly. Groups included 
(1) PBS-control group, (2) 0.06mg/kg/day AS2O3 group and (3) 0.12mg/kg/day AS2O3 
group. The dose of in vivo study was base on the results of in vitro study. 
Nude mice were treated with AS2O3 in PBS once every two days by intravenous 
injection. PBS-control group was injected with PBS only. The tumor size and body 
weight of the each mouse were measured before the treatment. 
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After a total 15 day treatment, the mice were sacrificed. The weight of the mice was 
recorded. All mice first anesthetized by intra-peritoneal (i.p.) injection of 0.1ml 
pentobarbital. Then, the mice were dissected and 0.5-0.8ml whole blood was withdrawn 
from the heart. The blood was transferred to a 1.5ml microflige tube that contained 20|il 
of heparin and was centrifuged at lOOOxg for 10 minutes at 4°C. After the centrifligation, 
the plasma was transferred to a new microfuge tube and stored at 4°C until enzyme assay 
was performed. 
The volume of tumor was calculated as follows: 
Volume of tumor (nW) = length (mm) x width (mm) x height (mm) 
Percentage of tumor growth 
=volume of tumor (t) (mm^) / volume of tumor (f) (mm^) x 100% 
where, volume of tumor (t) = the volume of tumor on day n after the treatment initiated 
volume of tumor (f) = the volume of tumor on the day one 
2.2.7.3 Toxicity of Arsenic Trioxide 
To assess the toxicity of AS2O3 after treatment, plasma enzymes activities were 
measured. After the plasma was collected, activities of four plasma enzymes, creatine 
kinase (CK), lactate dehydrogenase (LDH), alanine transaminase (ALT) and aspartate 
transaminase (AST), were measured by enzymatic diagnostic kits (Sigma). Increased 
activities of C K and L D H indicate heart tissue damage, while the increases of ALT and 
AST indicate liver tissue damage. 
The procedures of enzymatic activities measurement were done according to the 
protocol of the enzymatic kits. Briefly, for measuring C K and L D H activities, 25^1 of 
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plasma was mixed with 500 ml of C K or L D H reagent, respectively. The mixture was 
then incubated at 30°C for 3 minutes and 30 seconds for C K and LDH, respectively. The 
absorbance was measured at 340 nm by spectrophotometer (Beckman) for 2 minutes and 
1 minute for C K and LDH, respectively at 30 seconds interval. For measuring AST and 
ALT, 100}xl of plasma was mixed with 1 ml AST or ALT reagent and incubate at 37。C for 
1 minute. Absorbance was measured at 340 nm at 30 seconds interval for 2 minutes. 
The enzymatic activities were calculated as follows: 
Enzymatic activity (U/L) = (AAper min x TV x 1000)/ (6.22 x LP x SV) 
where A A per min = change in absorbance per minute at 340 nm 
TV = total reaction volume (ml) 
LP = light path 
6.22 = millimolar absorptivity of N A D P H at 340 
nm 
SV = sample volume 
1000 = conversion of units per ml to per liter 
thus, C K (U/L) = A A per min x 8200 
L D H (U/L) = AAper min x 3376 
AST (U/L) = AAper min x 1768 
ALT (U/L) = AAper min x 1768 
The mean value of the plasma enzymatic activities of the same group was then plotted 
against the corresponding treatments. 
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Chapter 3 
Anti-Proliferation effect of AS2O3 
on MDA-MB-231 cells 
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3.1 Study the Anti-proliferation Effect of AS2O3 on 
MDA-MB-231 Cells by MTT Assay 
Viable cells convert, MTT, from yellow colored salt to purple colored formazan, so 
the color changes indicate the percentage of cell survival after treatment. 
In this part, we explore the potency of anti-proliferation effect of AS2O3 on estrogen-
independent cells line, MDA-MB-231 cells. MDA-MB-231 cells were cultured in 
complete RPMI 1640 medium as a monolayer. Then, the cells were treated with a range 
of concentrations of AS2O3 prepared by serial dilute for 24，48 and 72 hours. After the 
treatment, M T T assay was performed to assess the effect of cell survival of AS2O3 on 
MDA-MB-231 cells. The results were shown in the Figure 3.1. The IC50 of MDA-MB-
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Fig 3.1 The anti-proliferate effect on MDA-MB-231 cells. MDA-MB-231 cells were 
treated with various concentrations of AS2O3 for 24, 48 or 72 hours. Mean 士 SD. n=4 
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3.2 Comparison of Anti-proliferation Effect of AS2O3 on 
MDA-MB-231 Cells to That of Tamoxifen 
Tamoxifen, a non-steroidal antiestrogen, is the most commonly used therapeutic 
drug in the chemotherapy of breast cancer patients (Jaiyesimi et al., 1995). However, it 
has been reported that tamoxifen has little effect on treating estrogen receptor a negative 
breast cancers (Swain, 2001). The anti-proliferation effect of tamoxifen on MDA-MB-231 
cells was also tested to compare with that effect of AS2O3 by M T T assay. 
MDA-MB-231 cells were incubated with a range of concentrations of tamoxifen or 
AS2O3 for 48 and 72 hours. After treatment, the IC50 of tamoxifen were 22.3|LIM, 18.3|LIM 
to MDA-MB-231 cells and IC50 of AS2O3 on MDA-MB-231 cells are 17.9|iM, 12.4|iM 
for 48 and 72 hours respectively (Fig 3.2). 
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(b) 72 h treatment 
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Fig 3.2 Compare anti-proliferate effect of AS2O3 and tamoxifen on MDA-MB-231 
cells. MDA-MB-231 cells were treated with different concentrations of tamoxifen or 
AS2O3 and (a) Incubated for 48 hours. IC50 of tamoxifen on MDA-MB-231 cells was 
22.3|XM, while the IC50 of AS2O3 was 17.9|liM. (b) Incubated for 72 hours IC50 of 
tamoxifen on MDA-MB-231 cells was 18.3|iM, while IC50 of AS2O3 was 12.4^M. Mean 
士 SD. n=4. 
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3.3 Study Toxicity of AS2O3 on Normal Breast Cells 
Line, 184B5 
Furthermore, 184B5 cells were used as a model to test the toxic effect of AS2O3 on 
normal breast cells. 184B5 cells line was established from normal mammary tissue 
obtained from a normal reduction mammoplasty (Stampfer, 1989) and were cultured in 
complete M E G M medium (Lu et al., 2003). 
As mentioned in section 1.5.1 AS2O3 was considered as toxic agent for many 
centuries. The toxic effects caused by acute exposure to arsenic trioxide are caused by its 
ability to bind to cellular proteins containing sulfhydryl groups. Arsenic trioxide has 
direct toxic effects on endothelial cells, increasing the permeability of small blood vessels. 
A dose as little as 1 to 2.5 mg/kg of arsenic trioxide may cause people dead (Agency of 
Toxic Substances & Disease Registry). Although evidence from clinical trial indicates 
that AS2O3 is harmless to patients with clinical dose and with careful monitor during 
treatment (Shen et al, 1997), it is necessary to investigate the toxicity of AS2O3 on normal 
breast tissue. 
The M T T assay was carried out to study the cytoxicity effect of AS2O3 on normal 
breast cancer cells, 184B5 (Fig 3.3). 
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Fig 3.3 Cytotoxicity effects of AS2O3 on 184B5 and MDA-MB-231 cells. 184B5 and 
MDA-MB-231 cells were treated with different concentrations of AS2O3 and (a) Incubated 
for 48 hours. IC50 of AS2O3 on 184B5 and MDA-MB-231 cells were 21.5|IM and 17.9|LIM 
respectively, (b) Incubated for 72 hours IC50 of AS2O3 on 184B5 and MDA-MB-231 cells 
were 18.6jiM andl2.4|aM respectively. Mean 士 SD. n=4 
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3.4 Summary 
In this part, the anti-cancer effect of AS2O3 on MDA-MB-231 cells was studied. 
According to the result of M T T assay, the IC50 of AS2O3 treated MDA-MB-231 cells are 
large than 20jiM, 18.4fxM and 12.1jiM after incubated with drug for 24, 48 and 72 hours 
respectively which indicated that AS2O3 can inhibit the proliferation of MDA-MB-231 
cells in a dose and time dependent manner (Table 3.1). 
AS2O3 was more effective to the anti-tumor effect of tamoxifen on MDA-MB-231 
cells, as the IC50 of AS2O3 is lower than that of tamoxifen treated cells. (Table 3.2) 
In addition, the cytotoxity of AS2O3 was investigated on human normal breast cells 
line, 184B5. The result demonstrated that MDA-MB-231 cells are more susceptible than 
the normal breast cells (Table 3.3). 
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Table 3.1 The ICsoof AS2O3 on MDA-MB-231 cells with 24, 48 and 72 hours treatment 
by M T T assay 
Time (h) 24 48 72 
~ I C 5 o ( _ ^ 183 m 
Table 3.2 Compare the anti-proliferation effect of AS2O3 and Tamoxifen on M D A - M B -
23 1 cells for 48 and 72 hours treatment using IC50. 
IC50 ( _ 
D m g 48li 72h 
Tamoxifen 22.3 18.3 
AS2O3 173 12A 
Table 3.3 Compare the cytotoxicity of AS2O3 on 184B5 and MDA-MB-231 cells for 48 
and 72 hours treatment using IC50. 
IC50 ( _ 
Cells Line 48h 72h 
18485 2L5 KG 
MDA-MB-231 VL9 UA 
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Chapter 4 
Mechanism of Growth Inhibition 
Effect of AS2O3 
on MDA-MB-231 cells 
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4.1 Cell Cycle Analysis of AS2O3 Treated MDA-MB-231 
Cells 
PI is a red-fluorescent nuclear and chromosome counterstain that can be used to 
stain DNA. It is commonly used to analyse the apoptotic, necrotic and normal cells. 
When it is excitated by 488nm laser beam, PI emits red light which will be detected by 
flow cytometry FL-2 channnal. The intensity of fluorescence is proportional to the amout 
of PI bound on DNA. The amount of PI bound on D N A is related to the D N A contents of 
the cells and histogram can draw from the data by plotting the number of cells against the 
intensity of fluorescence. Then, we can estimate the percentage of cells in sub-Gi, Gi, S 
and G2/M phase. 
Analysis was performed for the MDA-MB-231 cells treated with different 
concentrations of AS2O3 for 72 h. The result showed that there is an increase in sub-Gi 
phase indicated that AS2O3 may inhibit the growth of MDA-MB-231 cells by inducing 
apoptosis (Fig 4.1). An accumulation of cells in S and G2/M phase observed from the 
results indicated that cell cycle arrest may also occur in the MDA-MB-231 cells (Fig 4.1 
and Table 4.1). 
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Fig 4.1 Cell cycle of MDA-MB-231 cells treated with different concentration of 
AS2O3 for 72 hours. 3x10^ cells were seeded in each well of 6-well plates. After treated 
with AS2O3 for72 h, the cells were stained with PI. The populations of cells in sub-Gi, Gi, 
S and G2/M phase was determined by F AC Sort flow cytometer and analysed by WinMDI. 
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Table 4.1 The percentage of MDA-MB-231 cells distributions in sub-Gi, Gi, S and 
G2/M phase after treated with different concentrations of AS2O3 for 72 hours 
phase subGl GO/Gl S G2/M 
~control 134 63.65 11.77 1725 
3.125uM ^ 56.34 T i m 1926 
""“6.25uM 933 49.03 22.57 
12.5uM ^ 47.57 18!56 25.16 
25uM 14!59 36.04 21.80 28.79 
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4.2 Detection of DNA Fragmentation 
Apoptosis is known as programmed cells death. It can be characterized by changes 
in the plasma membrane, cell shrinkage, chromatin condensation and organized 
chromatin digestion to small fragments (“DNA ladders") (Bold et al., 1997). So the 
ability of AS2O3 to induce apoptosis on MDA-MB-231 cells was examined by D N A 
fragmentation assay. 
MDA-MB-231 cells were incubated with various concentrations of AS2O3 for 72 
hours. After treatment, the D N A contents were extracted and separated on 1.5% agarose 
gel. Ladder pattern was observed when the MDA-MB-231 cells were treated with 
6.25|aM, 12.5|^M and 25)^M AS2O3 (Fig 4.2). 
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Fig 4.2 Result of DNA fragmentation assay of MDA-MB-231 cells treated with 
AS2O3 for 72 hours. Lane M is the lOObp marker. Lane 1 is the control that cells 
incubated only with the medium. Lanes 2, 3, 4, 5 were cells treated with 3.125|iM, 
6.25|iM 12.5|iM and 25}xM AS2O3 respectively. A ladder pattern was observed under the 
concentration of 6.25}aM, 12.5jiM and 25|iM. 
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4.3 Detection of Apoptosis Induced by AS2O3 on MDA-
MB-231 Cells by Flow Cytometry 
Among the changes during the apoptosis, the changes in the plasma membrane are 
the earliest indicator. Annexin V is a Ca^^-dependent phospholipids-binding protein. It 
binds to cells with exposed phospholipids phosphatidylserine (PS). In common, PS 
locates at inner leaflet of the plasma membrane. In the case of apoptosis, PS translocates 
to the outer leaflet of the plasma membrance and be bond by Annexin V. When Annexin 
V was conjugated to fluorochrome, fluorescein isothiocyanate (FITC) which emits green 
fluorescence, which identifies cells undergo apoptosis by flow cytometry FL-1 channel. 
However, we can not distinguish apoptotic cells from necrotic cells by using Annexin V 
alone, since the necrotic cells are also Annexin V positive. PI bind to D N A double helix. 
Early apoptotic cells have integrated membrane (PI negative) while late apoptotic and 
necrotic cells loss membrane integrity (PI positive). Therefore, PI was used to distinguish 
apoptotic cells from necrotic cells by flow cytometry FL-3 channal (Vermes et al., 1995). 
After the MDA-MB-231 cells were treated, dot plots show an increase of percentage 
of apoptotic cells in a dose dependent manner (Fig 4.3). 
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Fig 4.3 The dot plots with the intensity of PI against Annexin V-FITC. 3x10^ cells 
were seeded in each well of 6-well plates. After treated with AS2O3 for 72 h, the cells 
were stained with PI and Annexin V-FITC. A shift of cell population to the right bottom 
quadrate was observed after AS2O3 treatment. 
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4.4 Regulation of Apoptotic Related Protein by AS2O3 on 
MDA-MB-231 Cells 
Apoptosis is a process of deliberate life relinquishment by a cell in a multicellular 
organism. It is one of the main types of programmed cell death (PCD), and involves an 
orchestrated series of biochemical events leading to a characteristic cell morphology and 
death. The process of cell undergo apoptosis is controlled by many cell signals through 
both intrinsic (mitochondrial) and extrinsic (death receptor) pathways. 
On one hand, apoptosis can be triggered by internal damage to the cell. For the 
intrinsic pathway, bcl-2 family proteins are involved. The proteins of the bcl-2 famly can 
be divided in to two parts: those of anti-apoptosis that are located on the surface of 
mitochondria and those of pro-apoptosis that are found in cytosol. They can react to the 
intercellular death signal and make holes on the mitochondrial membrance, causing 
cytochrome c to leak out (Reed et cd., 1996; A m a m and Cory, 2001). Cytochrome C will 
combine with other molecules to form aoptosomes to activate caspase-9, then other 
caspase which are known as cysteine proteases and one of the main executors of the 
apototic process (Hickman et al., 1996, Eamshaw et al., 1999). 
On the other hand, apoptosis can also be triggered by external signals. The death 
receptors such as Fas ligand, TNF alpha (TNFa) play an important role in external 
pathway of apoptosis. These receptors are integral membrane proteins with their recptor 
domain exposed at the surface of the cell and can mediated apoptosis and active caspase 
cascade in a short time (Ashkenazi et al., 1999, Belka_g^  a!., 2000, Wajant, 2002). 
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In addition to the death receptor, bcl-2 family and caspase proteins, there are many 
other molecules related to apoptosis which are substrates of caspase: (1) The enzymes 
involved in D N A repair for example poly (ADP-ribose) polymerase (PARP). (2) The 
structural nuclear proteins, for example lamins which is degradation by caspase 6 during 
apoptosis (3) The enzymes caused D N A fragmentation such as caspase activated DNase 
(CAD) 
In this part of the study, I use the Western blot analysis to examine the expression 
levels of apoptotic-related proteins to investigate apoptotic pathways involved in M D A -
MB-23 1 cells induced by AS2O3. 
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4.4.1 Expression Level of Bcl-2 and Bax Protein 
Human bcl-2 protein is a 26 kDa, membrane-associate protein. It is one of the key 
regulators of apoptosis. It is an anti-apoptotic protein among bcl-2 family which can 
promote cell survival by interfering with the activation of mitochondrial-related apoptotic 
pathway and by interacting with other bcl-2 related family members (Reed, 1994). 
Bax (B-9) is another member of Bcl-2 family. It is about 23kDa. Different from bcl-2, 
it is a pro-apoptotic protein. Overexpression of Bax will accelerates apoptotic death. It 
promotes apoptosis by competing with bcl-2 proper. Thus, the effects of bax and Bcl-2 
suppress each other, so that high bcl-2/bax ratio suppresses apoptosis whereas low bcl-
2/bax ratio triggers apoptosis (Adams and Suzanne, 1998). 
The bcl-2 and bax protein exprssion levels were studied by western blotting. After 72 
hours treatment, there is an obversely decrease in expression level of bcl-2 while there is 
no significant change on expression level of bax protein (Fig 4.4 and Fig 4.5). 
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Fig 4.4 Protein expression level of bcl-2 in MDA-MB-231 cells treated with AS2O3 
for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal amount of 
each sample were resolved by SDS-PAGE and probed with anti-bcl-2 antibody (1:100). 
Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 4, 5 were cells 
treated with 3.125)aM, 6.25|iM, 12.5|LIM and 25jLiM AS2O3 respectively. 
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Fig 4.5 Protein expression level of bax in MDA-MB-231 cells treated with AS2O3 
for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal amount of 
each sample were resolved by SDS-PAGE and probed with anti-bax antibody (1:100). 
Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 4, 5 were cells 
treated with 3.125|aM, 6.25|iM, 12.5|iM and 25|^M AS2O3 respectively. 
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4.4.2 Expression Level of Cytochrome C 
Cytochrome c or cyt c is a small heme protein found loosely associated with the 
inner membrane of the mitochondrion. The molecular weight of cytochrome C is about 
llkDa. It is essential to energy conversion in all aerobic organisms. When it released 
from mitochondrion, it acts as a factor necessary for activation of apoptosis by forming 
caspase cascade (Liu et al； 1996). The release of cytochrome seems to be controlled by 
bcl-2 family members (Kluck et al., 1997). 
The MDA-MB-231 cells were treated with various concentrations of AS2O3 for 72 
hours. Then, the western bolt analysis was performed. The result in the Fig 4.6 shows an 
increase of intensity in cytochrome c band with the increase of concentration of AS2O3. 
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Fig 4.6 Protein expression level of cytochrome c in MDA-MB-231 cells treated with 
AS2O3 for 72 hours. After 72 h treatment, cytosolic fraction proteins were extracted. 
Equal amount of each sample were resolved by SDS-PAGE and probed with anti-
cytochrome c antibody (1:100). Lane 1 is the control that cells incubated only with 
medium. Lanes 2, 3, 4 , 5 were cells treated with 3.125jiM, 6.25|xM，12.5|LIM and 25 ) I M 
AS2O3 respectively. 
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4.4.2 Expression Level of Cytochrome C 
Caspase is a family of cysteine-containing, aspartate-specific proteases. Caspase 9, 
also known as Apaf-3 is a 45 kDa protein exists as inactive proenzyme in cells. It is 
promoted by cytochrome c and catalyzed to the active form by forming a complex with 
Apaf-1 in the presence of dATP. Once caspase 9 is actived, it will promote the activation 
of other caspase such as the caspase 3, 6 and 7 (Eamshaw et al., 1999). 
The expression level of caspase 9 was studied by western blot analysis. A mouse 
monoclone anti-caspase-9 antibody was used to probe the sample. The pro-caspase 9 
expression level was shown in the Fig 4.7. As expected, the protein level decreased in the 
drug treated MDA-MB-231 cells when compare to the control group. 
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Fig 4.7 Protein expression level of caspase 9 in MDA-MB-231 cells treated with 
AS2O3 for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal 
amount of each sample were resolved by SDS-PAGE and probed with anti-caspase-9 
antibody (1:500). Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 
4, 5 were cells treated with 3.125FIM, 6.25^M, 12.5^M and 25|J.M AS2O3 respectively 
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4.4.4 Expression Level of FasL 
Two important examples of the direct initiation of apoptotic mechanisms in 
mammals include the TNF (tumour necrosis factor) -induced model and the Fas-Fas 
ligand-mediated. Fas, which known as CD95, is a cell surface death receptor. Fas ligand 
(Fas L) is the ligand of Fas receptor with a molecular weight form 26 to 40 kDa. FasL 
binds with Fas receptor to form the death-inducing signaling complex, activates the 
caspase 8 and induce the apoptosis (Algeciras-Schimnich et al, 2002). 
The expression level of Fas in MDA-MB-231 cells was studied by western blot 
analysis. The result was shown in the Fig 4.8. As expected, the protein level of FasL was 
upregulated in the drug treated MDA-MB-231 cells when compare to the cells treated 
only with medium. 
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Fig 4.8 Protein expression level of FasL in MDA-MB-231 cells treated with AS2O3 
for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal amount of 
each sample were resolved by SDS-PAGE and probed with anti-FasL antibody (1:100). 
Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 4, 5 were cells 
treated with 3.125|iM, 6.25|aM, 12.5jLiM and 25|iM AS2O3 respectively. 
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4.4.2 Expression Level of Cytochrome C 
Human caspase 8 protein appears as a 50/55kDa doublet in cytosol. The capase 8 
contains an aminoacid sequence enable it to interacte with Fas-associated death domain 
protein (FADD). F A D D then acts as an adapter molecule molecule and allow caspase 8 to 
become recruited to the cytoplasmic region of Fas following receptor activation. Caspase 
8 is produced as a proenzyme which is activated by cleaving to smaller subunit (Cohen et 
al., 1997). 
Studied by western blot analysis, the antibody recognizes the proform (50/55kDa 
doublet) of human caspase-8. (Fig 4.9) And the expression level of pro-caspase 8 
decreased siginifcantly in the MDA-MB-231 cells treated with AS2O3 when compare with 
the untreated cells. 
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Fig 4.9 Protein expression level of caspase 8 in MDA-MB-231 cells treated with 
AS2O3 for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal 
amount of each sample were resolved by SDS-PAGE and probed with anti-caspase-8 
antibody (1:100). Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 
4, 5 were cells treated with 3.125|LIM, 6.2512.5|iM and 2 5 | I M AS2O3 respectively 
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4.4.2 Expression Level of Cytochrome C 
Caspase 3, also know as CPP32, apopain and Yama，is one of the key mediate 
molecule of apoptosis. After the inactive 32kDa pro-caspase 3 is cleaved to the 17 or 11 
kDa active form by other family member of caspase, for example caspaseS, it will in turn 
be responsible for the cleavage of other key cellular proteins such as Poly (ADP-ribose) 
polymerase (PARP) and leads to apoptosis. Besides its role in activation of cellular 
proteins, it can also activate other caspase: caspase 6, 7 and 9 (Cohen et al., 1997). 
The exprssion level of caspase 3 protein was studied by western blotting. After 72 
hours treatment, there is an obversely decrease in expression level of pro-caspase-3 in the 
AS2O3 treated MDA-MB-231 cells to the cells treated only with RPMI medium. The 
result of the expression level of caspase 3 by western boltting was shown in Fig 4.10. 
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Fig 4.10 Protein expression level of caspase 3 in MDA-MB-231 cells treated with 
AS2O3 for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal 
amount of each sample were resolved by SDS-PAGE and probed with anti-caspase-3 
antibody (1:100). Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 
4, 5 were cells treated with 3.125jLiM, 6 . 2 5 ) I M , 12.5jLiM and 25 |LIM A S 2 O 3 respectively. 
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4.4.7 Expression Level of Poly (ADP-ribose) Polymerase 
(PARP) 
PARP involves D N A repair and programmed cell death. It is the first identified 
caspase substrate protein. During the apoptosis, caspase 3 cleaves the 116 kDa into 85 
kDa active form (Tewari et al., 1995). 
The expression level of PARP in MDA-MB-231 cells was studied by western blot 
analysis. PARP (H-250), a rabbit polyclonal anti-PARP antibody was used to probe the 
sample. The proform PARP protein expression level was shown in the Fig 4.11. As 
expected, the protein level decreased in the drug treated MDA-MB-231 cells when 
compare to the control group. 
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Fig. 4.11 Protein expression level of PARP in MDA-MB-231 cells treated with 
AS2O3 for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal 
amount of each sample were resolved by SDS-PAGE and probed with anti-PARP 
antibody (1:100). Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 
4, 5 were cells treated with 3.125|^M, 6.25juM, 12.5)^M and 25|LIM AS2O3 respectively 
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4.4.8 Expression Level of p53 
The tumor suppressor gene p53 plays an essential role in surveillance of D N A 
damage, and in regulation of the cell cycle and apoptosis. The wild-type p53 gene is 
essential for regulation of cell growth and loss of p53 function may be involved in the 
early steps of tumor formation through the survival of cells with genetic mutations. Oren 
et al reported in 1994 that p53 can arrest cells in the Gi phase of cell cycle to allow the 
D N A damage to repair, however, if the damage too serious to be repaired, it will induce 
apoptosis of the cells (Oren, 1994). A number of human cancers, including lung, colon 
have been shown to mutate in the p53 gene. Tumors that possess either mutation or 
deletion of the p53 gene are still capable of undergoing apoptosis, such as in breast 
cancer upon exposure to Taxol (Strobe 1 et al., 1996). It also has been demonstrated that 
p53 is capable of stimulating bax expression (Miyashita and Reed, 1995). 
Investigated by western blot analysis, the antibody recognizes 53 kDa human p53. 
(Shown in Fig 4.12) And the expression level of p53 is downregulated in the MDA-MB-
23 1 cells treated with AS2O3 when compare with the untreated cells. 
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Fig. 4.12 Protein expression level of p53 in MDA-MB-231 cells treated with AS2O3 
for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal amount of 
each sample were resolved by SDS-PAGE and probed with anti-p53 antibody (1:100). 
Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 4, 5 were cells 
treated with 3.125|iM, 6.25|^M, 12.5)iM and 25|iM AS2O3 respectively 
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4.5 Regulation of Cell Cycle Related Protein by AS2O3 
on MDA-MB-231 Cells 
The cell cycle is the series of events that take place in a cell between its formation 
and its replication. Most cells have a typical four phase cell cycle: Gi, S, G2 and M phase. 
Some cells may temporarily or reversibly stop division and enter a state of quiescence 
called Go phase. 
Cell cycle is a complicated process and it is controlled by many regulators. Regulatores 
work on the checkpoint of cell cycle process. At the end of the Gl and G2 phase, and 
after D N A replication in the S phase, it is checked for damages. At the end of the M 
phase a checkpoint stop cytokinesis, if the chromosomes are not properly aligned on the 
mitotic spindle. There are two main kinds of regulators involving in the cell cycle: cyclins 
and cyclin-dependent kinases (cdks). Cyclins bind to cdks to form cyclin-cdk complexes 
that regulates the cell cycle. The main types of cyclin-cdk complexes include cyclin D-
cdk4/6 for Gi phase, cyclin E-cdk2 for Gi to S phase transition, cyclin A-cdk2 for S 
phase, cyclin A/B-cdkl for G2 and M phases (Murray and Kirschner, 1991). As metioned 
in the section 4.4, p53 block the cell cycle at the checkpoint of Gi phase to allow the cell 
to repair D N A (Lee and Bernstein A, 1995). 
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4.4.2 Expression Level of Cytochrome C 
Cyclin B is a mitotic cyclin with a molecular weigh of 58 kDa. In mammals cyclin B is 
involved in G2/M phase transitions of the cell cycle associate with cdkl. The complex 
remains inactive until the completion of D N A synthesis and then activated by a specific 
protein phosphatase, Cdc 25. The amount of cyclin B (which binds to Cdkl) and the 
activity of the cyclin B-Cdk complex rise through the cell cycle until mitosis, when they 
fall abruptly due to degradation (Dunphy, 1994). 
As shown by the cell cycle analysis by PI staining (Table 4.1), there was an increase in 
percentage of cells in G2/M phase after MDA-MB-231 cells are treated with different 
concentration of AS2O3, indicating that AS2O3 may induce a cell cycle arrest at G2/M 
phase. The expression level of cyclin B was explored by western boltting. The result was 
shown in Fig 4.13. There is a marked increase in expression level of Cyclin B with the 
increasing concentration of AS2O3. 
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Fig. 4.13 Protein expression level of cyclin B1 in MDA-MB-231 cells treated with 
AS2O3 for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal 
amount of each sample were resolved by SDS-PAGE and probed with anti-cyclin B1 
antibody (1:500). Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 
4 , 5 were cells treated with 3 .125jLiM, 6.25}AM, 12.5)LIM and 2 5 J L I M A S 2 O 3 respectively. 
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4.4.2 Expression Level of Cytochrome C 
Cyclin E is expressed during Gl phase with a reduced molecular weight of about 50 
kDa. Cyclin E associated with cdk2 specifically regulates the transition from the Gi phase 
to the S phase of the cell cycle. A high level of cyclin E accelerates the transition of the 
cell through the Gi phase; however, p53 tumor suppressor gene inhibits the cyclin E-cdk2 
activity after D N A damage (Di Leonardo et al., 1994). 
Lindahl et al reported recently that cyclin E is of prognostic value in breast cancer. 
High levels of cyclin E in the tumor correlate with an aggressive tumor type and poor 
survival of the patients (Lindahl et al, 2007). 
The cyclin E exprssion level was studied by western blotting. After 72 hours 
treatment, there is no significant change on expression level of cyclin E protein (Fig 4.14). 
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Fig. 4.14 Protein expression level of cyclin E in MDA-MB-231 cells treated with 
AS2O3 for 72 hours. After 72 h treatment, total cellular proteins were extracted. Equal 
amount of each sample were resolved by SDS-PAGE and probed with anti-cyclin E 
antibody (1:100). Lane 1 is the control that cells incubated only with medium. Lanes 2, 3, 
4, 5 were cells treated with 3.125|iM, 6.25j^M, 12.5|iM and 25^M AS2O3 respectively. 
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4.6 Summary 
The results of the mechanism study indicated that AS2O3 inhibit the proliferation of 
MDA-MB-231 cells via induction of both cycle arrest and apoptosis which were shown 
in the results of cell cycle analysis (Fig 4.1，Table 4.1, Fig 4.2 and Fig 4.3). 
The results of western bolt analysis further confirmed the former results that: 
(1) As203-induced apoptosis was dependent on the extrinsic pathway, as shown by 
increase of FasL expression level (Fig 4.8), caspase 8 (Fig 4.9), caspase 3 (Fig 4.10) and 
PARP (Fig 4.11) activation. 
(2) AS2O3-induced apoptosis was dependent on the mitochondria intrinsic pathway, 
as shown by activation of caspase 9 (Fig 4.7), what's more, the increase of cytochrome c 
expression (Fig 4.6) and the decrease of bcl-2 expression, thus the increase ratio of 
Bax/bcl-2 (Fig 4.4 and Fig 4.5). 
(3) AS2O3 induced cell cycle arrest at G2/M phase, as shown by increase of cyclin B 
expression (Fig 4.13), whereas it did not induced Gi arrest for there is no change on 
cyclin E expression (Fig 4.14). 
(4) The tumor suppression gene p53 is not involved in the anti-proliferation effect of 
AS2O3 as shown in the Fig 4.12 that the expression level of p53 is downregulated in the 
AS2O3 treated MDA-MB-231 cells. 
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Chapter 5 
In Vivo Study of Anti-tumor Effect 
of AS2O3 
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5.1 Anti-tumor Effect of AS2O3 on Tumor Bearing Nude 
Mice 
In the previous study, AS2O3 has found to inhibit the growth of breast cancer cells in 
vitro by inducing apoptosis and cell cycle arrest. The anti-proliferation effects of AS2O3 
can be observed both on ERa positive and ERa negative breast cancer cells lines. I next 
investigate the anti-tumor and possible toxic effects of AS2O3 on nude mice. 
Four to six week female nude mice bearing tumor were used as the animal model. Each 
mouse was inoculated 1x10^ MCF-7 cells in PBS. A 0.72mg, 60-day releasing 17(3-
estradiol pellet (Innovative Research of America) was inoculated s.c. into the anterior 
part before inoculation of estrogen dependent MCF-7 cells. After the mice developed 
tumor, the mice were divided into 3 groups: PBS-control group, 0.06mg/kg/day AS2O3 
group and 0.12mg/kg/day AS2O3 group. Nude mice were treated with AS2O3 in PBS every 
two days and the body weight and tumor size were measured during the treatment and 
calculated after treatment. 
The results show a decrease of tumor growth in nude mice of AS2O3 treatment group 
(Fig 5.1) and during the treatment the body weight of the mice remains constantly (Fig 
5.2). The t-Test was carried out by the Microsoft Office Excel software to compare the 
significance between the results of each two treatment groups 
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Fig 5.1 The effect AS2O3 on the tumor growth in tumor bearing nude mice. The 
tumor size of the nude mice are measured by using electronic caliper and calculated with 
a formula: tumor size(mm^) = length (mm) x width (mm) x height (mm) every two days 
during treatment. The percentage of tumor growth was shown by compare the tumor size 
of the later days with the tumor size of the first day treatment. The first day treatment is 
noted as day 1. Data were mean士 S.D., n=7. t-Test was performed: p<0.05 between 
control group and 0.06mg/kg/day AS2O3 group; p<0.02 between control group and 
0.12mg/kg/day AS2O3 group 
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Fig 5.2 The changes of body weights of tumor bearing nude mice during treatment. 
The body weigh of nude mice were measured every two days during treatment with 
different concentration of AS2O3. The first day treatment is noted as day 1. Data were 
mean土 S.D., n=7. 
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5.2 Toxic Effect of AS2O3 on Normal Tissues 
Among the large amount of enzymes in the body, some of them are tissue specific. 
In normal situations, the level of these tissue specific enzymes is low in the plasma. 
When there is damage to the tissue which causes the tissue cell death, the enzymes will 
be released into the plasma. So measuring the activity of these tissue specific enzymes in 
the plasma enables us to detect whether there is damage to the related tissue. 
The side effects of AS2O3 are mainly report on the cardiac toxicity. The heart and 
liver are the two main tissue of the body. Activity of four enzymes in plasma was 
measured to study toxicity of AS2O3 on normal cells: Aspartate dehydrogenase (AST) 
which located mainly in liver, heart and skeletal; Alanine dehydrogenase (ALT) which 
located mainly in liver, kidney and heart; Creatine kinase (CK) which located mainly in 
heart and Lactate dehdrogenase (LDH) which is located mainly in heart. So the cardiac 
toxicity of AS2O3 can be assessed by measurement of plasma level of C K and LDH, while 
the hepatic toxicity by ALT and AST (Lo et al., 2002). 
After 15 days treatment the nude mice were sacrificed and the blood was collected 
from the heart. The plasma was separated for enzyme activity analysis following the 
protocols of the enzymatic kits. There was no significant change of AST and ALT 
activities in the plasma (Fig 5.3 and Fig 5.4) when compared with that of the PBS control 
after AS2O3 treatment for 15 days. 
For the cardiac toxicity of AS2O3, there is a slight increase of C K and LDH 
activities in the plasma (Fig 5.5 and Fig 5.6), when compared with that of the PBS 
control. During 15 day treatment, no death and hemolysis occurred in all groups. 
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Fig 5.3 Effect of AS2O3 on Aspartate dehydrogenase (AST) activity of nude mice. 
PBS, 0.06mg/kg/day and 0.12mg/kg/day AS2O3 was injected intravenously into nude 
mice every two days for 15 days. After treatment, the mice were sacrificed and the 
plasma was collected to perform enzyme assays. Normal mice injected with PBS were 
used as control for comparison. Data were mean土 S.D.，n二7. 
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Fig 5.4 Effect of AS2O3 on Alanine dehydrogenase (ALT) activity of nude mice. 
PBS, 0.06mg/kg/day and 0.12mg/kg/day AS2O3 was injected intravenously into nude 
mice every two days for 15 days. After treatment, the mice were sacrificed and the 
plasma was collected to perform enzyme assays. Normal mice injected with PBS were 
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Fig 5.5 Effect of AS2O3 on Creatin Kinase (CK) activity of nude mice. PBS, 
0.06mg/kg/day and 0.12mg/kg/day AS2O3 was injected intravenously into nude mice 
every two days for 15 days. After treatment, the mice were sacrificed and the plasma was 
collected to perform enzyme assays. Normal mice injected with PBS were used as control 
for comparison. Data were mean士 S.D., n=7. 
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Fig 5.6 Effect of AS2O3 on Lactate dehydrogenase (LDH) activity of nude mice. PBS, 
0.06mg/kg/day and 0.12mg/kg/day AS2O3 was injected intravenously into nude mice 
every two days for 15 days. After treatment, the mice were sacrificed and the plasma was 
collected to perform enzyme assays. Normal mice injected with PBS were used as control 
for comparison. Data were mean士 S.D., n=7 
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5.3 Summary 
In vivo study showed AS2O3 was able to inhibit the breast tumor growth in tumor 
bearing nude mice in a dose dependent manner (Fig 5.2). 
The enzyme activity analysis showed no significant increase of plasma level of 
specific tissue enzymes, AST, ALT, C K and L D H after 15 days treatment (Fig 5.3, 5.4, 
5.5 and 5.6). These results, together with the conctant body weight of the nude mice (Fig 






6.1 Anti-tumor Effect of AS2O3 on Breast Cancer 
In addition to the significant anti-cancer effect on APL, AS2O3 has been studied on 
its potential use in other types of Leukemia as well as solid tumor (Konig et al., 1997, 
Ling et al； 2002, Li et al., 2004). In the previous study of our group, AS2O3 was found to 
be able to inhibit the proliferation of ERa positive MCF-7 cells in vitro. Further 
mechanism study indicated AS2O3 induced apoptosis and cell cycle arrest on MCF-7 cells. 
And these effects were related to the ability of AS2O3 in regulating the ERa signaling 
pathway (Chow et al., 2004). 
Women patients of breast cancer at late stage always have their tissue contain ERa 
negative cells. To study the anti-tumor effect of AS2O3 on late stage breast cancer, M D A -
MB-23 1 cells line, an ERa negative breast cells line, was used to mimic the late stage of 
breast cancer in this study. The result indicated that the AS2O3 can inhibit the M D A - M B -
231 cells growth in a dose and time dependent manner (Fig 3.1 and Table 3.1) and 
inhibited the MDA-MB-231 cells growth at a much lower concentration than the 
tamoxifen did (Fig 3.2 and Table 3.2). 
Pharmacokinetics study performed by the Shen et al. during the treatment of APL 
suggested that it is safe to inject AS2O3 with a dose of lOmg/day for the plasma arsenic 
was rapidly eliminated and continuous administration of AS2O3 did not result in the 
accumulation of arsenic in plasma (Shen et al., 1997). Our data on nude mice showed that 
AS2O3 at concentration of 0.06mg/kg/day to 0.12mg/kg/day has no appeared toxicity on 
the animal. 
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6.2 Induction of Apoptosis and Cell Cycle arrest by 
A S 2 O 3 
Induction of apoptosis and cycle arrest are the most popular mechanisms studied on 
the chemotherapy drug these years. AS2O3 was reported to induce apoptosis in a wide 
range of cancer cell lines (Shao et al., 1998, Zhu et al., 1999，Kinjo et al, 2000, Li et al., 
2004., Chan et al., 2006). Apart from apoptosis, regulation of cell cycle is the other 
important mechanism involve in the anti-cancer effect AS2O3 (Lin et al” 2000, Park et al., 
2003, W u et al” 2004, Shao et al., 2005). In our study, AS2O3 at concentration 3.125|aM 
over induced apoptosis in MDA-MB-231 cells. This is confirmed by a typical D N A 
ladder pattern appeared in MDA-MB-231 cells appeared during D N A fragmentation 
assay (Fig 4.2). To further confirm this result, we tested the extemalization of PS by 
Annexin-V and PI staining. An increase in apoptotic cell was observed after the AS2O3 
treatment (Fig 4.3). Together with the detection of sub-Gi phase increase in cell cycle 
analysis (Fig 4.1 and Table 4.1), it was suggested that AS2O3 induced apoptosis in M D A -
MB-23 1 cells. Meanwhile, the increase of MDA-MB-231 cell population in G2/M phase 
indicated the AS2O3 induced G2/M cell cycle arrest in MDA-MB-231 cells (Fig4.1 and 
Table 4.1). 
In previous study, AS2O3 has been found to induce apoptosis in different human 
carcinoma cell lines by regulating the expression level of apoptotic related protein, 
however mechanisms under the AS2O3 induced apoptosis is quite different. Chow et al 
reported AS2O3 induced apoptosis in ERa positive breast cancer cell line MCF-7 was due 
to the collapse of mitochondrial membrane potential, up-regulation of tumor suppressor 
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gene p53 and regulation of ERa signaling pathway (Chow et al., 2004). As the M D A -
MB-23 1 cells are known to be ERa negative, the effect of AS2O3 on it does not involve 
ERa. And the features of MCF-7 cells and MDA-MB-231 cells are quite different from 
each other. For example, caspase 3 is a key factor for initiation of D N A fragmentation. 
D N A fragmentation was not detected during apoptosis in MCF-7 cells for that MCF-7 
cells do not express caspase 3 gene (Kurokawa et al., 1999), while MDA-MB-231 cells 
express caspase 3 (Yang et al., 2003) with D N A fragmentation occurring during 
apoptosis. In our study, the involvement of extrinsic apoptotic pathway in the apoptosis 
in MDA-MB-231 cells induced by AS2O3 was confirmed as the expression level of Fas 
receptor Ligand (FasL) increased (Fig 4.8) and the activation of caspase 8 (Fig 4.9), while 
an increase ratio of bax/bcl-2 (Fig 4.4 and Fig4.5), followed by increasing level of 
cytochrome c (Fig 4.6) and activation of caspase 9 (Fig 4.7) suggested the involvement of 
intrinsic apoptotic pathway. p53 is involved in both cell cycle and apoptosis. It was found 
to be upregulated and induce apoptosis through regulating bax (Miyashita and Reed, 1995, 
Zhao et al., 2000). From our study, the expression level of p53 is decreased (Fig 4.12) 
which indicated the p53 did not directly trigger the apoptosis in MDA-MB-231 cells. 
Since the function of p53 is let the cell repair from D N A damage, lacking of p53 may 
cause the prolong D N A damage in the MDA-MB-231 cells. And then the D N A damage 
may activate the intrinsic apoptotic pathway by down-regulating the expression level of 
bcl-2 (Fig 4.4). 
The induction of cell cycle arrest on various cancer cell lines by AS2O3 is mostly 
related to the arrest in Gi and G2/M phase (Lin et al., 2000, Park et al, 2003, W u et al., 
2004, Chow et al., 2004，Shao et al., 2005). Cyclin B1 associate with cdkl and remains 
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inactive in cytosol until it is activated by phosophorylation (McFowan and Russell, 1995) 
and cyclinB-cdkl induced G2/M phase arrest by prevention of the dephosphorylation of 
cyclinB-cdkl complex (Halloran and Fenton, 1998，Yin et al., 2001). In my study, the 
changes in expression levels of cyclin-Bl and p53 indicate that the AS2O3 inducing G2/M 
phase cell cycle arrest via prevention of the dephosphorylation of cyclinB-cdkl complex 
for the increase of cyclin-Bl (Fig 4.13) and decrease of p53 (Fig 4.12) expression. Cyclin 
E-cdk2 regulates the transition from Gi to S phase and p53 tumor suppressor gene 
inhibits the cyclin E-cdk2 activity after D N A damage (Lang et al” 2003, Di Leonardo et 
al., 1994). In my study, there is an significant decrease in percentage of MDA-MB-231 
cells in Gi phase (Table 4.1), together with the decrease of p53 expression (Fig 4.12) and 
no change of cyclin E expression in AS2O3 treated MDA-MB-231 cells in comparison to 
the control group, indicate that the p53 may not involve in the AS2O3 induction of cell 
cycle arrest for that p53 in the MDA-MB-231 cells may be non-functional or mutated 
(Hui et al., 2006). 
6.3 Side Effect of AS2O3 on Breast Cancer Treatment 
For thousands of year, AS2O3 was considered as a toxic agent in both Chinese and 
western society. Recent clinical use of AS2O3 in treating APL reported the possible 
adverse effect during treatment. The side effect of AS2O3 mainly detected in the heart 
disorders, for instance, the QT prolongation, torsade de pointes tachycardias (TdP), 
sudden death from heart attack (Zhang et al., 2001, Zhou et al., 2003, Ficker et al., 2004). 
The growth inhibition of AS2O3 on 184B5 cells was studied to investigate the toxic effect 
of AS2O3 on normal breast tissue. When the AS2O3 inhibited 50% MDA-MB-231 cells, 
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the percentage of survival of 184B5 cells was over 70% for 48 and 72 hours AS2O3 
treatment. And in a lower concentration of AS2O3 less than 12.5jLiM, MDA-MB-231 cells 
were more susceptible to the AS2O3 than the normal breast cells. In addition, the toxic 
effect of liver and heart tissues were studied in vivo on two main tissues in the body: heart 
and liver. The dosage of AS2O3 used is equivalent to that in in vitro study of MCF-7 cells 
(data not shown) and is less than the clinical application of the drug that the results 
suggested it was safe to be a medicine. In the study, we tested four tissue specific 
enzymes; two are located mainly in liver and two are located mainly in heart. There are 
no significant changes in plasma level of four enzymes (Fig 5.3, 5.4, 5.5 and 5.6)， 
showing there is no toxic effect of AS2O3 on both tissues with the dosage of 
0.06mg/kg/day and 0.12mg/kg/day AS2O3 treatment. 
In conclusion, AS2O3 was effective in treating breast cancers both early stage and 
late stage. The present study also provided promising data on the possible application of 





7.1 Future Prospectives 
Although we found that the AS2O3 inhibits the tumor growth through induction of 
apoptosis and cell cycle arrest, the detailed mechanisms were not fully investigated in this 
study. Apoptosis is a very complicated progress. Apart from the intrinsic pathway and 
extrinsic pathway of apoptosis, other molecules and pathways may also involve in it, for 
example the other members of bcl-2 family and caspase family. More cyclin and cdk 
should be studied as well as other cell cycle related proteins. There have been similarities 
between progression through cell cycle and induction of apoptosis. Many regulators have 
effect on both progresses. For example, the ErbB2 antisense in breast cancer, which is 
particularly over-expressed in breast carcinoma, have effect both on cell-cycle activation 
and on apoptosis in the breast cancer (Bold et al., 1997, Makin and Dive 2001). As the 
p53 found to have no direct effect on apoptosis and cell cycle arrest in MDA-MB-231, 
the mechanism cause the ineffective of p53 should also be studied. More experiments 
should be performed to get a full understand on mechanisms of AS2O3 induced apoptosis 
and cell cycle arrest. 
It has been reported that the anti-tumor effect AS2O3 on ERa positive breast cancer 
cell line MCF-7 included the ability of AS2O3 to regulate the ERa signaling pathway 
(Chow et al, 2004). Although the MDA-MB-231 cells are ERa negative, it expresses 
ERp on its surface and is defined as ERp positive. The ERa and ERp are the two forms 
of estrogen receptor and have the similar structure with each other. It is reasonable to 
investigate whether AS2O3 have effect on the ERp signaling. 
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As the breast cancers are solid tumor, AS2O3 can be directly injected s.c. at the site 
adjacent to the tumor. Without diluted by blood, the concentration of drug will be high 
for a period of time at tumor side after s.c. injection. In Comparison to i.v. injection, the 
amount of drug enters into the blood is lower than injected s.c. This will reduce the side 
effect on other tissues caused. Finally, the AS2O3 have anti-proliferation effect on both 
MCF-7 and MDA-MB-231 cells in vitro, the mechanisms of the AS2O3 effect are not the 
same for the two cell lines. In vivo anti-tumor effect of AS2O3 on tumor bearing nude 
mice with MDA-MB-231 cells should be investigated to confirm the in vivo anti-tumor 
effect of AS2O3 on advanced stage breast cancer. 
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